Discovering Bioactive Peptides and Characterizing the Molecular Pathways that Control Their Activity by Mitchell, Andrew
 Discovering Bioactive Peptides and Characterizing the Molecular
Pathways that Control Their Activity
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation No citation.
Accessed February 19, 2015 10:27:25 AM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:9406016
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAA

  
 
 
Discovering Bioactive Peptides and Characterizing the 
Molecular Pathways that Control Their Activity 
 
 
 
A dissertation presented 
 
by 
 
Andrew James Mitchell 
 
to 
 
The Department of Molecular and Cellular Biology 
 
in partial fulfillment of the requirements 
for the degree of 
Doctor of Philosophy 
in the subject of  
Biochemistry 
 
 
 
Harvard University 
Cambridge, Massachusetts 
 
May 2012 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © 2012 by Andrew James Mitchell 
All rights reserved. 
 iii 
Professor Alan Saghatelian          Andrew James Mitchell 
 
Discovering Bioactive Peptides and Characterizing 
the Molecular Pathways that Control Their Activity 
 
Abstract 
 Bioactive peptides constitute a major class of signaling molecules in 
animals and have been shown to play a role in diverse physiological processes, 
including hypertension, appetite and sleep. As a result, knowing the identity of 
these molecules and understanding the mechanisms by which they are regulated 
has basic and medical significance. In this dissertation, I describe the 
development and application of novel methods for discovering bioactive peptides 
and the molecular pathways that control their activity.  
 Recent analyses of mammalian RNAs have revealed the translation of 
numerous short open reading frames (sORFs). However, it is unknown whether 
these translation events produce stable polypeptide products that persist in the 
cell at functionally relevant concentrations. In Chapter 1, I describe a study in 
which we used a novel mass spectrometry-based strategy to directly detect 
sORF-encoded polypeptides (SEPs) in human cells. This analysis identified 115 
novel SEPs, which is the largest number of mammalian SEPs discovered in a 
single study by more than a factor of 25. We observed widespread translation of 
SEPs from non-canonical RNA contexts, including polycistronic mRNAs and 
sORFs defined by non-AUG start codons. We also found that SEPs possess 
 iv 
properties characteristic of functional proteins, such as stable expression, high 
cellular copy numbers, post-translational modifications, sub-cellular localization, 
the ability to participate in specific protein-protein interactions and the ability to 
influence gene expression. Taken together, these findings provide the strongest 
evidence to date that coding sORFs constitute a significant human gene class.  
 In chapter 3, I describe a study in which we combine quantitative in vivo 
peptidomics, classical biochemical experiments and pharmacological studies in 
animal models to elucidate the metabolism of the neuropeptide substance P in 
the spinal cord. We identified two physiological substance P metabolites: the N-
terminal fragments SP(1-9) and SP(1-7). Focusing our efforts on the SP(1-9)-
producing pathway, we determined that an activity sensitive to the inhibitor 
GM6001 is the dominant SP(1-9)-generating activity in the spinal cord. We also 
show that GM6001 treatment causes a nearly three-fold increase in endogenous 
substance P levels in the spinal cords of mice, highlighting the functional 
relevance of the pathway blocked by this inhibitor.  
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Chapter 1 
Discovering and Characterizing Human Short Open Reading Frame-
Encoded Polypeptides  
 
 
 
 
Alan Saghatelian and I designed and developed the SEP-discovery platform with 
help from Drs. Amir Karger and James Cuff on generating the custom 
polypeptide databases and related support. Dr. Sarah Slavoff and I performed 
the peptidomics experiments. Dr. Bogdan Budnik analyzed the samples on the 
mass spectrometer. Dr. Sarah Slavoff, Adam Schwaid and I analyzed the data, 
synthesized peptides and cloned constructs. Adam Schwaid and I performed the 
quantitative SEP measurements and prepared samples for the L1000 
experiment. Dr. Sarah Slavoff performed the heterologous expression 
experiments that defined the FRAT2-SEP start site and uncovered the FRAT2 
protein-protein interaction with P32. Willis Read-Button and Aravind 
Subramanian performed the L1000 assay and subsequent gene set enrichment 
analysis. Joshua Levin generated the RNA-seq data. Moran Cabili and John Rinn 
assembled the K562 transcriptome from the RNA-seq data and culled the 
lincRNAs. 
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1.1 Introduction 
Short open reading frames (sORFs) in the 5ʼ-untranslated region (5ʼ-UTR) of 
eukaryotic mRNAs (uORFs) are well studied (1) and several have been shown to 
produce polypeptides (2, 3). In addition to uORFs, a handful of other sORFs in 
bacteria (4), viruses (5), plants (6, 7), Saccharomyces cerevisiae (8), 
Caenorhabditis elegans (9), insects (10, 11), and humans (12) have been 
discovered to encode polypeptides. Notable among them are the peptides 
encoded by the polycistronic tarsel-less (tal) gene in Drosophila, which are as 
short as 11 amino acids and regulate fly morphogenesis (10, 11).  
 Recently, computational analysis of the mouse transcriptome using 
improved gene-prediction algorithms has suggested that sORF-encoded 
polypeptides (SEPs) are significantly underrepresented in current protein 
catalogues (13), leading to speculation that coding sORFs constitute an 
unrecognized mammalian gene class. This hypothesis was bolstered by 
subsequent ribosome profiling studies in mouse embryonic stem cells, which 
found evidence that hundreds of sORFs in the mouse transcriptome are engaged 
by the protein translation machinery. However, since these studies did not 
directly detect the presence of any sORF-encoded polypeptides (SEPs), it 
remains unclear whether sORFs are widely translated into polypeptides that 
persist in the cell at functionally relevant concentrations. Indeed, follow-up 
experiments on sORFs identified as being translated by ribosome profiling failed 
to identify any polypeptide expression (14), indicating that at least some of the 
implicated sORFs are false positives. 
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 While no general approach exists for discovering SEPs, several attempts 
have been made to systematically identify these molecules. In E. coli, for 
example, experiments in which predicted sORFs were epitope-tagged revealed 
18 SEPs (15). In another example, a combination of computational and 
experimental approaches identified 299 potentially coding sORFs in S. 
cerevisiae, four of which were confirmed to produce protein and 22 of which 
appeared to regulate growth (8). Finally, in human cells, an unbiased proteomics 
approach identified a total of four SEPs (defined here as polypeptides that are 
synthesized on the ribosome at a length of 150 amino acids or less) between the 
K562 and HEK293 cell lines with a length distribution of 88-148 amino acids (16). 
 The discordance between the small number of SEPs detected in human 
cells (16) and the large number of coding sORFs described by ribosome profiling 
(17) and computational methods (13) leaves open the possibility that SEPs are 
not produced as predicted by these methods or else are rapidly degraded and 
therefore not detectable. Indeed, one might speculate that sORFs are translated 
as a unique mode of gene regulation whereby the process of translation itself 
rather than the synthesized product is the functional agent, or as part of a 
“checkpoint” or stalling mechanism in the trafficking of functional RNAs, or 
perhaps simply due to stochastic binding of ribosomes to pseudo-initiation sites 
that arise in the genome by chance. 
Thus, there is a need for an approach that can directly detect and validate the 
products of translated sORFs on a global scale. We therefore developed a novel 
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strategy for SEP discovery that integrates an optimized peptidomics and 
bioinformatics platform with a rigorous evaluation procedure based on manual 
spectra analysis and use of synthetic standards. Applying this approach to 
human cells, we uncovered 118 unannotated SEPs, which is the largest number 
of human SEPs ever reported in a single study by approximately a factor of thirty. 
We also analyze SEP-encoding sORFs to reveal several unexpected features of 
SEP translation, including widespread initiation at non-AUG start codons and 
polycistronic expression. Perhaps most intriguingly, though, we find that SEPs 
possess properties characteristic of functional proteins, such as stable 
expression, high cellular copy numbers, post-translational modifications, 
subcellular localization, the ability to participate in specific protein-protein 
interactions and the ability to influence gene expression. Taken together, these 
findings provide the strongest evidence to date that coding sORFs constitute a 
significant human gene class.  
 
1.2 Peptidomics analysis of human myelogenous leukemia cells 
Peptidomics is a liquid chromatography-tandem mass spectrometry (LC-MS/MS)-
based technique aimed at the comprehensive visualization and analysis of 
endogenous peptides (18, 19). Peptidomics experiments are distinguished from 
traditional proteomics experiments in that the core workflow contains steps 
designed to preserve and enrich small polypeptides (18-21). In the context of the 
present study, the use of peptidomics is intended to increase the total number of 
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SEPs detected and expand the detection range to include shorter SEPs by 
eliminating the signal-suppressing effects of large proteins. We isolated peptides 
from K562 cells (22), a human leukemia cell line, because these cells were the 
subject of the most successful SEP discovery effort to date and we could 
therefore use the previously reported SEPs to benchmark our performance (16).  
 Endogenous peptides were isolated using an optimized peptidomics 
workflow developed in our laboratory (21) (Figure 1.1), with great care being 
taken to reduce proteolysis. Proteolysis is detrimental because the processing of 
cellular proteins greatly increases the complexity of the peptidome, which 
deteriorates the signal-to-noise ratio during the subsequent analysis (23). 
Practically, isolation of the peptidome from K562 cells is accomplished by boiling 
a frozen cell pellet to lyse the cells and simultaneously inactivate any proteases. 
Heat inactivation of proteolytic activity is common practice in peptidomics and 
has led to the identification of known peptides from cells or tissues to 
demonstrate its reliability (24-27). After cell lysis, the lysate is passed through a 
molecular weight cut-off filter to separate small polypeptides (hereafter, 
“peptidome”) from the rest of the proteome. We prepared two sets of samples, 
one enriched using a 30 kDa MWCO filter and another enriched using a 10 kDa 
MWCO filter. This was done to maximize our coverage of the smallest SEPs 
while ensuring that larger SEPs were not overlooked.  
 After isolating the peptidome, we reduced and alkylated the sample to 
eliminate disulfide bonds and prevent them from re-forming; covalent links  
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Figure 1.1 Peptidomics workflow. First, we boil a frozen K562 pellet to lyse the 
cells and simultaneously eliminate protease activity. Second, we isolate the 
peptidome by passing the cell lysate through a molecular weight-cutoff filter. 
Next, we reduce and alkylate the peptide mix to eliminate disulfide bonds and 
prevent them from re-forming prior to analysis; covalent links between peptide 
side chains can make definitive MS/MS spectra interpretation difficult or 
impossible. After that, we fractionate the peptidome by electrostatic repulsion-
hydrophilic interaction chromatography (ERLIC), which separates analytes by 
hydrophobicity and isoelectric point. This step simplifies the sample to allow for 
deeper coverage of the peptidome. Finally, we analyze each ERLIC fraction by 
reversed-phase-liquid chromatography-tandem mass spectrometry (RP-LC-
MS/MS), thus generating a collection of spectra from which the identities of the 
peptides can be determined. 
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between peptide side chains can make definitive MS/MS spectra interpretation 
difficult or impossible. The sample was then exposed to trypsin to generate 
peptide fragments that are ideal for subsequent LC-MS/MS analysis. However, 
prior to analysis, the trypsinized peptides were fractionated by electrostatic 
repulsion-hydrophilic interaction chromatography (ERLIC)(28), which separates 
peptides based on their hydrophobicity and isoelectric point. ERLIC fractionation 
has been reported to significantly improve detection sensitivity in proteomics 
experiments (29), so we included this step to deepen our peptidome coverage. 
Finally, each ERLIC fraction was analyzed by nano-flow reversed-phase (RP)-
LC-MS/MS system with a high-resolution mass spectrometer. 
 
1.3 Analyzing peptidomics data to identify novel SEPs 
To identify SEPs, it was necessary to develop a modified protocol for LC-MS/MS 
data analysis. Standard proteomics and peptidomics approaches identify 
peptides by matching experimentally observed spectra to databases of predicted 
spectra based on annotated genes. Such databases would not necessarily 
contain the predicted spectra of SEPs. We therefore created a custom database 
containing all polypeptides that could possibly be translated from the annotated 
human transcriptome (The National Center for Biotechnology Reference 
Sequence, or RefSeq (30)) or the reverse-complement thereof (Figure 1.2A). We 
were interested in polypeptides that could be translated from the reverse-
complement of annotated transcripts because of reports of pervasive 
transcription of the antisense strands of eukaryotic genes ((31)).  
 8 
 
 
 
 
 
Figure 1.2 Discovering SEPs. (A) An LC-MS/MS-based peptidomics platform 
was used to profile K562 cells. The MS/MS data were searched against a custom 
protein database derived from human RefSeq transcripts to identify polypeptides 
in K562 cells. Tryptic peptides that were exact matches to a segment of an 
annotated protein were computationally filtered. In addition, tryptic peptides that 
differed from annotated proteins by only a single amino acid were also removed 
to avoid the false identifications arising from point mutations in known proteins. 
The sequence assignment of these putative SEPs was validated by visual 
inspection of the tandem MS spectra. Finally, we referenced K562 RNA-seq data 
to verify that that detected peptides were derived from a sORF rather than an 
unannotated ORF longer than 450 nucleotides or a mutated annotated ORF. Any 
tryptic peptide that fit these criteria was identified as arising from a novel human 
SEP. (B) Tandem MS spectra were visually inspected to ensure that there was 
sufficient sequence coverage to unambiguously differentiate the peptide from 
similar known protein sequences. The spectra were required to have a precursor 
mass error of less than 5 ppm and a sequence tag of five consecutive b- or y-
ions. (C) We experimentally validated some of these assignments by chemically 
synthesizing the diagnostic peptide and comparing its tandem MS spectra of that 
of the endogenous peptide. This particular peptide is derived from a sORF found 
on a non-coding RNA (chr16:86563805-86589025). 
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 Using Sequest, an analysis program used to identify peptides from MS/MS 
spectra (32, 33), we compared >200,000 MS/MS peptide spectra to this RefSeq-
derived polypeptide database. This resulted in 6548 unique peptide 
identifications. We arrived at a tentative list of SEPs by keeping only those tryptic 
peptides that differed by at least two amino acids from every annotated protein to 
minimize the possibility of false positives arising from polymorphisms in 
annotated genes. We then winnowed the list down further to a candidate set by 
eliminating all peptide-spectrum matches (PSMs) with an Sf score of less than 
0.4, which is a typical threshold used in proteomics studies to cull PSMs that can 
be used with confidence to identify proteins (34). (The Sf score is a composite 
metric generated by the SEQUEST algorithm to indicate the strength of a PSM. It 
takes into account the preliminary score, the cross-correlation and the difference 
in strength between the highest scoring PSM and the second highest scoring 
PSM for a given spectra.) 
 Due to the small size of SEPs, it is unlikely that an unbiased peptidomics 
experiment will detect more than one tryptic fragment of a given SEP. This 
contrasts with standard proteomics studies, which, on account of the numerous 
tryptic fragments generated from larger polypeptides, will typically uncover two or 
more peptides to support the presence of a protein. Realizing that we would likely 
not be able to rely on the confidence contributed by the inherent redundancy of 
multiple-peptide protein identifications for SEP discovery, we submitted the 
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candidate PSMs to a rigorous evaluation procedure to ensure the highest 
confidence in each peptide identification. 
 First, we discarded any PSM with an Sf score of less than 0.75. This 
eliminated over 95% of the candidate set. We then visually examined each 
remaining MS/MS spectrum to ensure that it met a stringent set of criteria (Figure 
1.2B). In particular, we required that there be a sequence tag of five consecutive 
b- or y-ions, a precursor mass error of <5 ppm, and sufficient sequence coverage 
to unambiguously differentiate each peptide from every annotated protein 
sequence. This step reduced the remaining peptide pool by approximately 75%, 
for a total of 39 SEPs, three of which were previously reported and thus served 
as positive controls (16) and 36 of which are novel. Our PSM evaluation 
procedure therefore selected the highest quality ~1% of the peptide 
identifications in our original candidate set. As a check on the effectiveness of 
this procedure, we compared the experimentally collected MS/MS spectra of 
several identified peptides to that of identical synthetic peptides (Figure 1.2C). 
The spectra of the synthetic peptides were nearly identical to those of the 
endogenous peptides, confirming the identifications and validating our spectra 
evaluation procedure. 
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1.4 Probing the human transcriptome using deep RNA sequencing 
technology 
Although we were extremely careful in evaluating peptide-spectra matches to 
ensure that the tryptic peptides we identified were present in the sample, it 
occurred to us that there were still several potential sources of false positives that 
we had not eliminated. For one thing, we were not able to exclude the possibility 
that some of the identified peptides were produced from a long ORF on an RNA 
that was not catalogued in RefSeq (30) rather than from a sORF on an annotated 
transcript, as we suspected was the case. Indeed, since it is probable that not all 
RefSeq genes will be expressed in a given cell line, we could not even be sure 
that the transcripts to which we had ascribed SEPs were present in K562. 
Additionally, a recent report had indicated that mRNAs can undergo post-
transcriptional modifications that lead to alternate protein sequences (35). This 
phenomenon could also lead to the misidentification of SEPs. Lastly, although we 
had only admitted peptides whose sequence was at least two amino acids 
different from the nearest annotated protein sequence, it was still conceivable 
that a point mutation in an annotated gene could have led to an erroneous SEP 
identification. 
 Having a detailed and comprehensive knowledge of the K562 
transcriptome would enable us to rule out these potential sources of false 
positives. We therefore deep-sequenced K562 cellular RNA and assembled it 
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into the complete K562 transcriptome (Figure 1.3). Poly-adenylated RNA and 
total RNA were isolated separately from cultured K562 cells and cDNA libraries 
were generated from each sample. These libraries were then sequenced using 
Illumina high-throughput sequencing technology and the resulting reads were 
aligned to the human genome using the splice junction mapper TopHat (36). 
Finally, Cufflinks (36) was used to assemble the transcriptome. Including mono-
exonic RNAs, this analysis yielded over 700,000 unique transcripts. 
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Figure 1.3 Generating the complete transcriptome of K562 cells. Poly-
adenylated RNA and total RNA were isolated separately from cultured K562 cells 
and cDNA libraries were generated from each sample. These libraries were then 
sequenced using Illumina high-throughput sequencing technology and the 
resulting reads were aligned to the human genome using the splice junction 
mapper TopHat (36). Finally, Cufflinks (36) was used to assemble the 
transcriptome. 
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1.5 Validating SEPs encoded by annotated transcripts 
We wanted to determine whether the 39 RefSeq transcripts to which we had 
assigned SEPs in our previous discovery effort were actually present in K562. 
Crosschecking these transcripts with our assembled RNA-seq data revealed that 
37/39 SEPs were present. Interestingly, the implicated antisense transcript, the 
existence of which had never before been experimentally verified, was present in 
the sample.  
 Next, we wanted to verify that there were no long, unannotated ORFs that 
could be producing the detected SEPs. We therefore searched the 37 detected 
peptides that we had assigned to these transcripts against a theoretical protein 
database generated by in silico translation of the complete K562 transcriptome 
using the BLAST algorithm (37). All 37 SEPs mapped uniquely to the annotated 
transcript sORF to which they had been assigned in our initial study (Table 1.1). 
With this analysis, then, we eliminated the possibility that the detected peptides 
had arisen from point mutations in annotated genes, longer unannotated ORFs, 
or post-transcriptional modification or editing of RNAs and were thereby left with 
a high-confidence set of annotated transcript-derived SEPs. 
 The 37 SEPs discovered through analysis of RefSeq transcripts fall into 
five major categories: (i) those located in the 5ʼ-UTR, (ii) those located in the 3ʼ-
UTR, (iii) those located (frameshifted) inside the main coding sequence (CDS),  
(iv) those located on non-coding RNAs (ncRNAs), and (v) those located on 
antisense transcripts (Figure 1.4). Many of these SEPs appear to be derived from  
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Table 1.1 List of high-confidence SEPs derived from RefSeq transcripts. When 
present, an upstream in-frame AUG was assumed to be the initiation codon. If no 
upstream AUG was present, the initiation codon was assigned to an in-frame 
near-cognate non-AUG codon embedded within a Kozak-consensus sequence 
(38). In a few cases, neither of these conditions was met, so the codon 
immediately following an upstream stop codon was used to determine maximal 
SEP length. Chromosome coordinates are from the University of California Santa 
Barbara Genome Browser, assembly H19. 
Transcript 
Category 
Detected Peptide Sf 
Score 
Start 
Codon 
SEP 
Length 
(aa) 
Chromosome 
Coordinates 
RefSeq AAPGALPEAAVGPR 0.81 ATG 96 
chr9:13925635
2-139264369 
strand=-  
RefSeq AGAPAVGLLLANER 0.93 GTG 39 
chrX:16859470
-16888534 
strand=- 
RefSeq 
QLPPAAAVGDAGQLGR, 
APGGAAAGPGAPGCGG
AGGQGPAPGGAAAAAA
R 
0.91, 
0.98 ACG 103 
chr10:9909220
1-99094454 
strand=- 
RefSeq 
ATPGLQQHQQPPGPGR, 
ATPPGGTGHEGLSGGAA
DVASGVGSGR  
0.92, 
0.95 ATG 83 
chr9:13955736
6-139565706 
strand=+ 
RefSeq 
IVVDELSNLK, 
QQQNSNIFFLADR, 
NILDELKK, EYQEIENLDK  
0.9, 
0.89, 
0.74, 
0.87 ATG 96 
chr2:19052619
5-190535440 
strand=+ 
RefSeq TAPSSTATTASASCAATR 0.96 ATG 62 
chr7:15064665
7-150675423 
strand=- 
RefSeq LQVGPADTQPR 0.93 ATG 88 
chr9:12361207
7-123639492 
strand=- 
RefSeq STAACQTSSIATR 0.87 ATG 97 
chr14:1038005
38-103809402 
strand=+ 
RefSeq GSSAAVGPR 0.84 stop 78 
chr16:8957482
7-89607413 
strand=+ 
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Table 1.1 (Continued) 
Transcript 
Category 
Detected Peptide Sf 
Score 
Start 
Codon 
SEP 
Length 
(aa) 
Chromosome 
Coordinates 
RefSeq TAAAAAAGTITRPR 0.78 GTG  102 
chr8:64080459-
64125260 
strand=+ 
RefSeq 
GVGGQAALFAAGR, 
AGGDLPLQPQPGGAAAR
, 
AAQAFFPAAELAQAGPE
R 
0.96, 
0.93, 
0.96 GTG 88 
chr8:14489739
9-144897840 
strand=- 
RefSeq AVAAAAAAAPDPGGR 0.81 acg 91 
chr10:9828812
8-98346562 
strand=- 
RefSeq GGLGAASIAADGAPR 0.86 ctg 115 
chr4:12273761
6-122745077 
strand=- 
RefSeq SSTPAPPQGQFLPPSI 0.78 acg 74 
chr7:10046477
1-100471014 
strand=+ 
RefSeq VAVEEGLPGDPVAER 0.94 acg 107 
chr11:6568675
0-65689023 
strand=+ 
RefSeq EGSVHPQVE  0.76 atg 87 
chr10:1019920
55-102005758 
strand=- 
RefSeq 
GAIGGGGAGVQGQTAG
AR 0.91 atg 143 
chr5:18065003
9-180662529 
strand=+ 
RefSeq VAAVAVGSQAVLQILSR 0.9 atg 77 
chr19:4271328
6-42721897 
strand=- 
RefSeq WTSSTSSPNTSGAPR 0.94 atg 77 
chr19:1294933
1-12969791 
strand=+ 
RefSeq NPPLVQDTVSGK 0.9 atg 111 
chr1:15052239
1-150532570 
strand=+ 
RefSeq QTAFGKWYESLLNNR  0.78 stop 63 
chr3:19336360
2-193386115 
strand=+ 
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Table 1.1 (Continued) 
Transcript 
Category 
Detected Peptide Sf 
Score 
Start 
Codon 
SEP 
Length 
(aa) 
Chromosome 
Coordinates 
RefSeq TAAAAAAGTITRPR 0.78 GTG  102 
chr8:64080459-
64125260 
strand=+ 
RefSeq 
GVGGQAALFAAGR, 
AGGDLPLQPQPGGAAAR, 
AAQAFFPAAELAQAGPER 
0.96, 
0.93, 
0.96 GTG 88 
chr8:14489739
9-144897840 
strand=- 
RefSeq AVAAAAAAAPDPGGR 0.81 acg 91 
chr10:9828812
8-98346562 
strand=- 
RefSeq GGLGAASIAADGAPR 0.86 ctg 115 
chr4:12273761
6-122745077 
strand=- 
RefSeq SSTPAPPQGQFLPPSI 0.78 acg 74 
chr7:10046477
1-100471014 
strand=+ 
RefSeq VAVEEGLPGDPVAER 0.94 acg 107 
chr11:6568675
0-65689023 
strand=+ 
RefSeq EGSVHPQVE  0.76 atg 87 
chr10:1019920
55-102005758 
strand=- 
RefSeq 
GAIGGGGAGVQGQTAGA
R 0.91 atg 143 
chr5:18065003
9-180662529 
strand=+ 
RefSeq VAAVAVGSQAVLQILSR 0.9 atg 77 
chr19:4271328
6-42721897 
strand=- 
RefSeq WTSSTSSPNTSGAPR 0.94 atg 77 
chr19:1294933
1-12969791 
strand=+ 
RefSeq NPPLVQDTVSGK 0.9 atg 111 
chr1:15052239
1-150532570 
strand=+ 
RefSeq QTAFGKWYESLLNNR  0.78 stop 63 
chr3:19336360
2-193386115 
strand=+ 
RefSeq TWLPSCEDLTLPGGR  0.92 atg 50 
chr7:15879972
4-158814542 
strand=+ 
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Table 1.1 (Continued) 
Transcript 
Category 
Detected Peptide Sf 
Score 
Start 
Codon 
SEP 
Length 
(aa) 
Chromosome 
Coordinates 
RefSeq AVAGAAAGAGGR 0.79 atg 73 
chr19:1305950
8-13067950 
strand=- 
RefSeq AEEQPGLGPGAAGR 0.94 atg 149 
chr7:10003296
2-100034242 
strand=- 
RefSeq 
RAVPAQGLLQSTPTCMP
WTP  0.84 atg 54 
chr1:16006115
6-160064154 
strand=- 
RefSeq NTTQESLEKGP 0.78 stop 32 
chr22:4174038
3-41756157 
strand=+ 
RefSeq EALNEFLTR 0.87 stop 22 
chr4:16990876
2-169911558 
strand=- 
RefSeq AEPLQTAGQAGR 0.83 atg 59 
chr11:1189645
97-118966163 
strand=- 
RefSeq AGNLILLQ 0.82 stop 23 
chr3:12494564
0-125042272 
strand=- 
RefSeq STTIGGMNQR 0.77 atg 26 
chr12:4873223
6-48745011 
strand=- 
RefSeq ERPANSLIDQCSQR 0.8 atg 54 
chr2:13113030
9-131132956 
strand=+ 
RefSeq VFFKNLLAFAR 0.9 stop 22 
chr6:80194734-
80199064 
strand=- 
RefSeq AELSFLNR  0.84 atg 70 
chr16:8656380
5-86589025 
strand=- 
RefSeq 
LLPLGASPAGVVGGGLA
PPR 0.93 atg 85 
chr22:2136807
3-21368526 
strand=- 
RefSeq SLSSYGACSR 0.89 stop 71 
chr17:3544192
8-35444379 
strand=+ 
 19 
 
Table 1.1 (Continued) 
Transcript 
Category 
Detected Peptide Sf 
Score 
Start 
Codon 
SEP 
Length 
(aa) 
Chromosome 
Coordinates 
RefSeq FLPVDLSLLR 0.78 atg 90 
chr1:15553279
5-155708399 
strand=+ 
RefSeq GPSGTQEMGPLSR 0.95 atg 102 
chr19:3610043-
3626771 
strand=- 
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Figure 1.4 Overview of SEPs. (A) RNA maps illustrating the major categories of 
sORFs that are translated into SEPs. Categories include sORFs in the 5ʼ 
untranslated region (5ʼUTR), sORFs in the coding sequence (CDS), sORFs in the 
3ʼ untranslated region, sORFs on non-coding RNAs (ncRNAs), and sORFs on 
transcripts antisense to annotated RefSeq transcripts.The gray arrow represents 
the RNA, the blue arrow represents annotated protein CDS (if present), and the 
yellow arrow represents the sORF. The numbers mark the boundaries of each 
element of the transcript in nucleotide bases from the 5ʼ end of the transcript. 
 (B) Incidence of SEPs by sORF category. 
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polycistronic mRNAs, which is interesting because this phenomenon has 
historically been thought to be rare in eukaryotes. However, our findings here are 
consistent with those of ribosome profiling studies (17).  
 
1.6 Discovering SEPs encoded by long intergenic non-coding RNAs 
(lincRNAs) 
One intriguing feature of our analysis of RefSeq RNAs was the discovery of 
coding regions within transcripts that are annotated as non-coding. Since 2002, 
when long non-coding RNAs were first established as a transcriptional class 
through the sequencing of full-length cDNA libraries in mouse (39), interest in the 
functional properties of these molecules has grown rapidly. Commonly defined as 
transcripts that may posses mRNA-like properties but which lack ORFs longer 
than 100 amio acids, several dozen lncRNAs have now been shown to act as 
regulators of diverse cellular processes in mammals. For example, XIST 
contributes to X chromosome inactivation in by coating the inactivated 
chromosome (40); HOTAIR and COLDAIR interact with multiple protein 
complexes, including the polycomb-group protein Polycomb Repressive Factor 2 
(PRC2), to control skin development (41, 42); and H19 and KCNQ1OT1 interact 
with chromatin and a host of protein complexes to effect imprinting (43, 44). 
However, although RNAs such as these are known to play a direct, mechanistic 
role in carrying out their functions, there are numerous other putatively functional 
lncRNAs whose specific role has not been elucidated. In these cases, it is not 
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clear whether the transcript possesses an intrinsic function or rather performs 
through its coding potential1.  
The question of whether all transcripts that meet the traditional lincRNA 
definition are in fact non-coding has spawned efforts to discern a priori between 
novel SEP-encoding transcripts and bona fide non-coding RNAs. Notably, Lin et 
al have developed a comparative genomics-based gene prediction algorithm 
called PhyloCSF, which outperforms other available algorithms at identifying 
small protein-coding regions in genomic sequences (49). However, recognizing 
that some coding sORFs will be too small for even sensitive algorithms to identify 
and also that many coding sORFs may be recently evolved, we wondered 
whether our experimental approach to SEP discovery might make a nice 
complement to computational approaches.  
Recognizing that a majority of putative lincRNAs are not listed in RefSeq, 
we generated an extensive catalogue of nominally non-coding RNAs from our 
K562 RNA-seq data according to a previousy published protocol (50) (Figure 
1.3). Our lincRNA culling protocol was as follows. First, we removed any 
transcripts with a non-lincRNA annotation. Second, we scanned each transcript 
in all three frames to identify regions that could code for one of the protein 
domains catalogued in the protein family database Pfam (51). Transcripts 
                                                
1 It is important to note, however, that these possibilities are not exclusive. In E. 
Coli, for example, the sugar transport-related sRNA (SgrS) transcript helps cells 
recover from glucose-phosphate stress by base-pairing with the mRNA ptsG to 
bring about its degradation via RNase E (45, 46) and also by encoding a 43 
amino acid functional peptide called SgrT that prevents glucose uptake, probably 
by regulating the glucose transporter, PtsG (47, 48) 
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containing such regions were removed. We then removed all transcripts 
containing an ORF that appeared to be conserved at the protein coding level, as 
indicated by a positive phylogenetic codon substitution frequency score 
(PhyloCSF) (49). From the remaining pool of transcripts, we selected those that 
were multiexonic and originated from intergenic regions of the genome; these 
composed our lincRNA pool. We then generated a theoretical protein database 
by in silico-translating these transcripts in three frames and used this database to 
analyze our peptidomics datasets. 
Ribosome profiling experiments in mouse cells indicate the presence of 
translated sORFs on nearly half of the lincRNAs analyzed (17), which is much 
higher than expected (52-54). By contrast, our peptidomics analysis identified 10 
SEP-encoding lincRNAs (Table 1.2), which represents just 0.5% of the1866 
lincRNAs detected in our RNA-seq analysis of K562. This disparity may result 
from a number of factors, including false positive identifications by ribosome 
profiling techniques of (14). Additionally, ribosome profiling may identify rare 
translational events that do not generate enough protein to be detected by LC-
MS/MS, since mass spectrometry is biased towards the detection of more 
abundant peptides (55). It is also possible that some of the sORFs identified by 
ribosome profiling may produce polypeptides that are rapidly degraded and 
therefore would be undetectable using any analytical approach. Finally, the 
disparity may be a consequence of the fact that the study in question significantly 
undersampled lincRNAs: only 30 lincRNAs were examined when mammalian  
 24 
Table 1.2 List of high-confidence SEPs derived from lincRNA transcripts. When 
present, an upstream in-frame AUG was assumed to be the initiation codon. If no 
upstream AUG was present, the initiation codon was assigned to an in-frame 
near-cognate non-AUG codon embedded within a Kozak-consensus sequence 
(38). In a few cases, neither of these conditions was met, so the codon 
immediately following an upstream stop codon was used to determine maximal 
SEP length. Chromosome coordinates are from the University of California Santa 
Barbara Genome Browser, assembly H19. 
Transcript 
Category 
Detected Peptide Sf 
Score 
Start 
Codon 
SEP 
Length 
(aa) 
Chromosome 
Coordinates 
lincRNA 
THLGTEGQCDLPGAGGP
AR 0.98 stop 100 
chr10:11925853
-11937442 
strand= 
lincRNA CPFVLLMSSMILLR 0.81 STOP 33 
chr10:11980633
2-119859641 
strand=+ 
lincRNA QVLITNKNQ 0.81 ATG 29 
chr11:65266565
-65274602 
strand=- 
lincRNA QRIPCVVILTK 0.84 stop 73 
chr19:23278060
-23286908 
strand=+  
lincRNA KTLPMMGMIR 0.75 stop 30 
chr2:107137814
-107160732 
strand=+  
lincRNA QVNEETLK 0.78 stop 143 
chr3:107852804
-107857456 
strand=+  
lincRNA KNLFQNTSR 0.79 stop 59 
chr4:10069715-
10074643 
strand=- 
lincRNA LDMNPKK 0.79 ATG 60 
chr5:67726254-
67730308 
strand=- 
lincRNA IYQEEKK 0.84 stop 75 
chr7:26438339-
26538594 
strand=+ 
lincRNA RAGYSELE 0.87 ATG 69 
chr7:96251318-
96293650 
strand=- 
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cells typically contain thousands of such transcripts. Future work coupling 
ribosome profiling with mass spectrometry should help resolve these questions 
and provide a better understanding of the factors governing SEP expression.  
 
1.7 Discovering SEPs encoded by unannotated transcripts 
Recognizing that the RefSeq- and lincRNA-derived databases did not contain 
every SEP that could be encoded by transcripts present in K562, we generated a 
theoretical protein database by in silico-translating all of our K562 RNA-seq 
transcripts. Searching this database against our data sets and subjecting the 
resulting PSMs to our evaluation workflow yielded an additional 66 novel, high-
confidence SEPs (Table 1.3).  
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Table 1.3 List of high-confidence SEPs derived from K562 RNA-seq transcripts. 
When present, an upstream in-frame AUG was assumed to be the initiation 
codon. If no upstream AUG was present, the initiation codon was assigned to an 
in-frame near-cognate non-AUG codon embedded within a Kozak-consensus 
sequence (38). In a few cases, neither of these conditions was met, so the codon 
immediately following an upstream stop codon was used to determine maximal 
SEP length. Chromosome coordinates are from the University of California Santa 
Barbara Genome Browser, assembly H19. 
Transcript 
Category 
Detected Peptide Sf 
Score 
Start 
Codon 
SEP 
Length 
(aa) 
Chromosome 
Coordinates 
non-
annotated APEPGAVLAPAEVVLR 0.95 agg 119 
chr22:47048295
-47073068 
strand=+  
non-
annotated NALQQENHILDGVK 0.96 stop 52 
chr15:91565384
-91574477 
strand=+ 
non-
annotated LLVSGSPSAETLPLR 0.94 atg 128 
chr5:34914296-
34925392 
strand=+ 
non-
annotated ALAQGSLTPSQIYSA 0.91 aag 52 
chr22:17092426
-17095991 
strand=+ 
non-
annotated LSAPQPGPDILQAPAR 0.81 GTG 89 
chr19:54693858
-54697432 
strand=+  
non-
annotated VYIFQPVFEQYAK 0.92 atg 54 
chr15:55609385
-55613829 
strand=- 
non-
annotated NEQTELLYNK 0.9 stop 18 
chr12:11864994
4-118650075 
strand=+ 
non-
annotated ILEDFLPPSSSRPQS 0.84 stop 42 
chr2:85132483-
85133801 
strand=+ 
non-
annotated DLPGVAPPRPSLSLSGP 0.83 atg 65 
chr9:130209955
-130216851 
strand=-  
non-
annotated 
AAASGQPRPEMQCPAE
QTEIK 0.81 atg 58 
chr5:14664778-
14699800 
strand=+ 
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Table 1.3 (Continued) 
Transcript 
Category 
Detected Peptide Sf 
Score 
Start 
Codon 
SEP 
Length 
(aa) 
Chromosome 
Coordinates 
non-
annotated KINIEIR 0.8 ctg 46 
chr5:17966062
5-179718930 
strand=- 
non-
annotated KLEITSI 0.88 stop 25 
chr5:10819130
9-108191755 
strand=+ 
non-
annotated KLQLQC 0.75 stop 120 
chr20:5598194
9-55984389 
strand=- 
non-
annotated KLSLLEL 0.79 stop 47 
chr5:33479130-
33479598 
strand=+ 
non-
annotated KLVSEIK 0.78 stop 17 
chr20:5127012
5-51270250 
strand=- 
non-
annotated KNILEPK 0.89 stop 15 
chr16:1196199
1-11972092 
strand=+ 
non-
annotated KPLEPLL 0.78 agg 26 
chr14:5517878
8-55179023 
strand=+ 
non-
annotated KQGGFVQVSANAL 0.75 atg 136 
chr22:3201463
3-32026837 
strand=- 
non-
annotated KYPPPPP 0.81 stop 20 
chr14:7520154
1-75205240 
strand=- 
non-
annotated LNINQSIAVSTATQR 0.96 AGG 55 
chr2:20032292
8-200323580 
strand=+ 
non-
annotated LPGQATTQQTFDQR 0.88 stop 54 
chr19:5616509
1-56185542 
strand=+ 
non-
annotated LVSAVLAGKE 0.75 CTG 43 
chr1:7863564-
7864928 
strand=- 
non-
annotated MNFILK 0.75 atg 49 
chr3:44912513-
44913077 
strand=+ 
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Table 1.3 (Continued) 
Transcript 
Category 
Detected Peptide Sf 
Score 
Start 
Codon 
SEP 
Length 
(aa) 
Chromosome 
Coordinates 
non-
annotated PAVAAATLHLPAAPEGPH 0.78 atg 49 
chr7:10016985
2-100183655 
strand=- 
non-
annotated QELIGASLHTAR 0.75 stop 119 
chr1:22854474
3-228549628 
strand=+ 
non-
annotated RIQVEQTR 0.81 atg 63 
chr9:15055076-
15056573 
strand=+ 
non-
annotated RSVFPLLK 0.8 stop 22 
chr10:6968165
7-69833652 
strand=- 
non-
annotated 
TSDAPRPSATPPGADPLN
SAGPGAR 0.81 stop 103 
chr19:5573796
1-55770381 
strand=- 
non-
annotated VTSWDGQNPPR 0.76 ATG 50 
chr12:1296629
2-12982891 
strand=+ 
non-
annotated AAPGPTAAAAAQASAAAR 0.82 CTG 108 
chr2:23157758
3-231685792 
strand=+ 
non-
annotated RLLIPPEK 0.82 stop 45 
chrX:5214450-
5216144 
strand=+ 
non-
annotated SPTTDSYGIPQGCK 0.89 stop 40 
chr1:17591397
3-176153786 
strand=- 
non-
annotated APLLVKD 0.75 stop 15 
chr10:9777257
3-97772956 
strand=+  
non-
annotated PDEIIFK 0.75 stop 50 
chr2:17678592
1-176794931 
strand=+ 
non-
annotated DYILSLEMFSILLWG 0.77 stop 33 
chr3:88101102-
88108113 
strand=- 
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Table 1.3 (Continued) 
Transcript 
Category 
Detected Peptide Sf 
Score 
Start 
Codon 
SEP 
Length 
(aa) 
Chromosome 
Coordinates 
non-
annotated EDNFILK 0.77 CTG 37 
chr7:155093676
-155102099 
strand=- 
non-
annotated LNLYEIK 0.78 stop 52 
chr12:10434440
1-104350979 
strand=+ 
non-
annotated KIIYDK 0.78 ATG 35 
chr3:173924415
-173924516 
strand=+  
non-
annotated FGGFSLK 0.79 stop 63 
chr15:48995625
-48997517 
strand=+  
non-
annotated HGHSFPDPGLLLQNQGD 0.79 stop 122 
chr7:66386236-
66423532 
strand=+ 
non-
annotated FEIFGEK 0.8 stop 37 
chr4:164444822
-164451827 
strand=+  
non-
annotated HDASSSPLGPPR 0.8 stop 55 
chr16:87435666
-87438903 
strand=- 
non-
annotated EEAYFR 0.83 stop 23 
chr1:95657105-
95663161 
strand=-  
non-
annotated 
CLVYVLDLITDACTIKPLFN
K 0.86 stop 43 
chr9:130128866
-130129660 
strand=+  
non-
annotated 
ASPGEAGPAGGAAAGQG
APR 0.89 stop 73 
chr1:16905808-
16970994 
strand=- 
non-
annotated 
GAWGGGQLATAGSGPG
QR 0.96 ATG 70 
chr17:62205639
-62207524 
strand=- 
non-
annotated DTEVLINTMSK 0.79 ATT 27 
chr1:4036227-
4073316 
strand=+  
non-
annotated VYKWLLCNVE 0.78 ATG 41 
chr1:157243513
-157253900 
strand=+  
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Table 1.3 (Continued) 
Transcript 
Category 
Detected Peptide Sf 
Score 
Start 
Codon 
SEP 
Length 
(aa) 
Chromosome 
Coordinates 
non-
annotated KPVFLLLLSIR 0.85 STOP 32 
chr11:3532972-
3542051 
strand=+  
non-
annotated FIPTEAWYSAGR 0.79 ATG 86 
chr11:8278312
9-82805398 
strand=+  
non-
annotated IKFLLAPEENK 0.86 ATG 43 
chr16:3054772-
3058645 
strand=+ 
non-
annotated FYPDYIK 0.77 TTG 22 
chr11:1297053
1-13011090 
strand=-  
non-
annotated QMSSNILK 0.76 stop 50 
chr15:3100851
8-31061502 
strand=+  
non-
annotated VAHENYMKFK 0.82 stop 59 
chr21:3534540
0-35353552 
strand=+ 
non-
annotated GIALGDIPNAR 0.94 GTG 18 
chr6:68590370-
68642035 
strand=+  
non-
annotated VLLDQHQR 0.8 stop 23 
chr6:14116713
1-141219546 
strand=- 
non-
annotated YYELQRGTR 0.84 AAG 43 
chr15:5906027
3-59063173 
strand=-  
non-
annotated GEMERGEIK 0.81 ATG 18 
chr17:4137343
9-41383338 
strand=- 
non-
annotated CQDILEAGKR 0.85 ATC 70 
chr19:2344150
0-23457032 
strand=- 
non-
annotated DLGSPMLK 0.76 ATG 52 
chr2:23598100-
23604170 
strand=-  
non-
annotated TASPYSRPE 0.75 ATG 58 
chr2:66653867-
66660602 
strand=- 
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Table 1.3 (Continued) 
Transcript 
Category 
Detected Peptide Sf 
Score 
Start 
Codon 
SEP 
Length 
(aa) 
Chromosome 
Coordinates 
non-
annotated LTVAGQGR 0.75 ATG 66 
chr20:4173737-
4176599 
strand=+  
non-
annotated SPFWAGQGQSR 0.85 GTG 104 
chrX:11842549
2-118469573 
strand=+ 
non-
annotated NLAGGSGLIP 0.76 stop 41 
chrX:1515320-
1517852 
strand=- 
non-
annotated AAALQFDLR 0.94 stop 23 
chr21-
35303432-
35308177 
strand=+ 
non-
annotated 
AQHGVHSNTASPGLPAG
APR 0.96 agg 66 
chr7:15077818
0-150780257 
strand=- 
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1.8 Identifying post-translationally modified SEPs 
Functional proteins are commonly phosphorylated as a means of controlling their 
activity and many bioactive peptides are amidated at the c-terminus to prevent 
degradation by exopeptidases. We wondered whether SEPs undergo the same 
post-translational modifications. To answer this question, we reanalyzed our 
peptidomics data sets against the custom databases we generated from human 
RefSeq transcripts and K562 RNA-seq data using the SEQUEST (32) algorithm 
with specialized parameters designed to enable the identification of 
phosphorylated or c-terminally amidated peptides. While we did not detect post-
translational modification of any of the SEPs we had previously discovered, the 
analysis yielded five additional novel SEPs that are post-translationally modified 
(Table 1.4). All of these SEPs were phosphorylated and one was also c-
terminally amidated. 
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Table 1.4 List of high-confidence post-translationally modified SEPs derived from 
K562 RNA-seq transcripts. When present, an upstream in-frame AUG was 
assumed to be the initiation codon. If no upstream AUG was present, the 
initiation codon was assigned to an in-frame near-cognate non-AUG codon 
embedded within a Kozak-consensus sequence (38). In a few cases, neither of 
these conditions was met, so the codon immediately following an upstream stop 
codon was used to determine maximal SEP length. “@” indicates that the 
preceding residue is phosphorylated and “[“ indicates that the terminus is 
amidated. Chromosome coordinates are from the University of California Santa 
Barbara Genome Browser, assembly H19. 
Transcript 
Category 
Detected Peptide Sf 
Score 
Start 
Codon 
SEP 
Length 
(aa) 
Chromosome 
Coordinates 
non-
annotated VTLNLFLTS@IK 0.85 stop 49 
chr21:38122898
-38126719 
strand=+ 
non-
annotated SLGGILFTIIS@K 0.93 CTG 30 
chr16:89735690
-89738512 
strand=- 
non-
annotated 
IFLITIQDFIIAVIIVHS@T@
DSLQRLV 0.79 CTG 147 
chr15:77471130
-77474523 
strand=+ 
non-
annotated MLNFILIS@ILERA 0.75 ATG 14 
chr9:139557366
-139565706 
strand=+ 
non-
annotated 
PGIGAGTPVGPKVVGS@
L[ 0.80 stop 35 
chr12:3949920-
3950581 
strand=- 
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1.9 Exploring the global properties of SEPs 
 In total, we discovered 118 unannotated SEPs, three of which were 
previously reported and thus served as positive controls (16), and 115 of which 
are novel. This is the largest number of SEPs ever reported in a single study by 
approximately a factor of 30, which demonstrates the superior coverage afforded 
by our approach.  
 Wishing to explore the global properties of SEPs, we examined the size 
distribution and start codon usage of the molecules we had discovered. Because 
we perform our peptidomics analysis on trypsin-digested samples, we do not 
obtain full protein-level SEP sequence coverage and in particular do not directly 
observe the N terminus. We therefore used the following convention when 
assigning start sites to SEP-encoding sORFs. When present, the upstream-most 
in-frame AUG was assumed to be the initiation codon. If no upstream AUG was 
present, the initiation codon was assigned to an in-frame near-cognate non-AUG 
codon embedded within a Kozak-consensus sequence (38). In a few cases, 
neither of these conditions was met, so the codon immediately following an 
upstream stop codon was used to determine maximum SEP length.  
 Using this approach, we estimated the SEPs to range in length between 
14-149 amino acids, with the majority (>70%) being <75 amino acids (Figure 
1.5A). If we take a more conservative approach by using an AUG-to-stop or 
upstream-stop-to-stop, we obtain a similar SEP length distribution and retain our 
smallest SEPs, including the 14-mer (Figure 1.5B). As the shortest human SEP  
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Figure 1.5 Length distribution of high-confidence SEPs. (A) SEP length 
distribution estimated by defining sORFs as follows: when present, an upstream 
in-frame AUG was assumed to be the initiation codon. If no upstream AUG was 
present, the initiation codon was assigned to an in-frame near-cognate non-AUG 
codon embedded within a Kozak-consensus sequence (38). In a few cases, 
neither of these conditions was met, so the codon immediately following an 
upstream stop codon was used to determine maximal SEP length. (B) Length 
distribution determined by defining sORF initiation sites as the codon immediately 
3ʼ of the stop codon upstream of the detected peptide unless an AUG was 
present, in which case the upstream-most AUG was defined as the start.  
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previously identified by mass spectrometry was 88 amino acids long (16), it is 
clear that our approach provides superior coverage of small SEPs. This is 
significant because many previously characterized, functional SEPs are under 50 
amino acids (4, 10-12). 
 Another interesting feature of our results is the preponderance of non-
canonical translation start sites: 62% of the detected SEPs do not initiate at AUG 
codons (Figure 1.6). This finding is consistent with the results of ribosome 
profiling experiments in mouse, which indicate that, globally, most ORFs contain 
non-AUG start sites (17). In addition, the human SEP start codon usage 
distribution we propose is similar to that observed by ribosome profiling in mouse 
(e.g. CUG is the second most common used codon in both data sets) (17).  
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Figure 1.6 Probable start codon-usage distribution of SEP-encoding sORFs. 
Codon usage was estimated using the following sORF-defining convention: 
When present, an upstream in-frame AUG was assumed to be the initiation 
codon. If no upstream AUG was present, the initiation codon was assigned to an 
in-frame near-cognate non-AUG codon embedded within a Kozak-consensus 
sequence (30). 
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1.10 Testing SEP expression from RefSeq transcripts 
Though in vitro experiments have shown that the eukaryotic translation 
machinery is capable of initiating translation at non-AUG codons and ribosome 
profiling experiments have indicated that non-AUG initiation is common in mouse, 
the preponderance of non-canonical translation start sites among the discovered 
SEPs is striking (Figure 1.6). We therefore wished to verify that our SEPs could 
be translated from non-AUG start sites. Moreover, because a majority of the 
discovered SEPs appear to arise from polycistronic transcripts, which is a 
phenomenon thought to be rare in eukaryotes, we sought to verify that the 
implicated full-length annotated transcripts of SEPs with AUG starts were 
competent to produce SEPs. 
 Constructs were designed to produce full-length mRNAs, including 5ʼ and 
3ʼ UTRs, that matched those in the RefSeq database (56). We selected sORFs in 
the 5ʼ-UTR, the 3ʼ-UTR, or frameshifted within the CDS, and encoded a FLAG 
epitope tag at the 3ʼ-end of each sORF (so that initiation is unperturbed). The 
uORFs ASNSD1-SEP, PHF19-SEP, FRAT2-SEP, YTHDF3-SEP and EIF5-SEP 
all produced cytoplasmically localized polypeptides, as detected by anti-FLAG 
immunofluorescence in transfected HEK293T cells (Figure 1.7A). (We refer to 
SEPs by appending “-SEP” to the name of the annotated CDS nearest the sORF; 
the sORF is given the same name but italicized.) Importantly, the fact that 
FRAT2-SEP andYTHDF3-SEP, which do not have upstream AUG codons,  
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Figure 1.7 Expression of SEPs. (A) Transient transfection of HEK293T cells with 
constructs containing a cDNA sequence corresponding to the full-length RefSeq 
mRNA (i.e., including the 5ʼ- and 3ʼ-UTRs). We appended a C-terminal FLAG-tag 
on the SEP coding sequence that could be detected by immunofluorescence. In 
these images the nuclei are stained with DAPI (blue) and the SEPs are detected 
with anti-FLAG antibody (green). ASNSD1-SEP, PHF19-SEP, and EIF5-SEP are 
all derived from sORFs in the 5ʼ-UTR (uORFs); cells expressing EIF5 are 
indicated with a white arrow. Two additional 5ʼ-UTR sORFs, FRAT2-SEP and 
YTHD3-SEP, produce SEPs initiating with a non-AUG codons. Finally, DEDD2-
SEP (CDS) and H2AFx-SEP (3ʼ-UTR) were not translated from the RefSeq 
RNAs, which is consistent with a scanning model of eukaryotic translation. (B) 
Diagrams of the SEP-encoding RNAs used to produce the results depicted in A 
(the diagrams for ASNSD1 and DEDD2 are shown in Figure 1.3A). The gray 
arrow represents the RNA transcript, the blue arrow represents annotated protein 
CDS and the yellow arrow represents the sORF. The numbers mark the 
boundaries of each element of the transcript in nucleotide bases from the 5ʼ end 
of the transcript. 
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Figure 1.7 (continued) 
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Figure 1.7 (continued)  
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produced SEPs verifies that sORFs with non-AUG start codons are translated 
(Figure 1.7A). 
 By contrast, the DEDD2-SEP sORF was not translated from the full-length 
RefSeq construct (Figure 1.7A). DEDD2-SEP is frameshifted deep within the 
main CDS of the DEDD2 transcript, so according to the scanning model of 
translation (57) it is not expected that this downstream sORF would be translated 
(Figure 1.7B). Similarly, the 3ʼ-UTR-embedded H2AFx-SEP was similarly not 
translated from the full-length mRNA construct (Figure 1.7A). One possible 
explanation for these observations is that the DEDD2-SEP and the H2AFx-SEP 
are translated from splice variants of their respective annotated transcripts that 
are present in K562 cells but are not in the RefSeq database. In any case, it 
would seem that not all SEPs that derive from a segment of an annotated 
transcript are translated from a bicistronic mRNA. 
 
1.11 Alternative splicing of annotated protein coding genes generates SEP-
producing transcripts 
We identified a truncated DEDD2 mRNA in the RNA-seq data wherein the first 
start codon is that of the DEDD2-SEP sORF, making the transcript ideal for 
translation of DEDD2-SEP by the traditional ribosome scanning mechanism 
(Figure 1.8). This supports the hypothesis that alternative splicing of annotated 
protein coding genes is one mechanism by which SEP-producing transcripts are 
produced. However, we were not able to clearly identify a truncated version of the  
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Figure 1.8 Alternative splicing of SEP-encoding transcripts. The expression of 
the DEDD2-SEP in K562 cells may be explained by the existence of an 
alternative splice form of the DEDD2 RNA (DEDD2_RNA2), the first start codon 
of which initiates DEDD2-SEP. In this figure, the gray arrow represents the RNA, 
the blue arrow represents annotated protein CDS (if present), and the yellow 
arrow represents the sORF. 
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H2AFx transcript in the K562 RNA-seq data. It is possible that a truncated H2AFx 
mRNA variant is present in K562 cells but did not give rise to the sequencing 
reads necessary to resolve it from the full-length H2AFx transcript.  
 
1.12 Confirming a non-AUG start site and investigating the mechanism of 
bicistronic expression 
Since such a large proportion of SEPs putatively initiate at non-AUG sites, we 
wanted to rigorously identify the alternate start codon of one these sORFs. C-
terminally FLAG-tagged FRAT2-SEP was expressed from the full-length mRNA 
construct in HEK293T cells and immunoprecipitated; mass spectrometry of the 
purified protein (Figure 1.9) was consistent with initiation at an ACG triplet 
embedded within a Kozak consensus sequence (38) (Figure 1.10A). Mutating the 
ACG to an ATG resulted in increased FRAT2-SEP translation while deletion of 
this ACG abolished FRAT2-SEP production, as assessed by Western blotting, 
thus confirming our assignment (Figure 1.10B). In addition, mutation of the Kozak 
consensus sequence to less favorable residues led to markedly lower FRAT2-
SEP expression, which demonstrates the importance of the Kozak sequence at 
non-AUG initiation sites. 
 The scanning model of translation provided an explanation as to why the 
DEDD2 mRNA is not bicistronic; we hypothesized that upstream alternate start 
codons could provide a mechanism to promote polycistronic gene expression via 
leaky scanning. To test whether FRAT2 mRNA is bi-cistronic, we prepared a 
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FRAT2 construct where the SEP and the downstream CDS were tagged with 
different epitopes (Figure 1.10C), permitting their simultaneous detection by 
immunoblotting with two antibodies. We found that the FRAT2 RNA is bi-
cistronic, as FRAT2 and FRAT2-SEP are both expressed (Figure 1.10C).  
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Figure 1.9 Identifying the start site of FRAT2-SEP. MALDI-MS of 
immunoprecipitated FRAT2-SEP-FLAG provides a polypeptide with a molecular 
weight of 9905, which corresponds to an ACG initiation codon with methionine as 
the first amino acid.  
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Figure 1.10 Characterization of the non-AUG initiation codon of the FRAT2-SEP 
sORF. (A) An ACG triplet embedded in a Kozak consensus sequence was 
identified as the FRAT2-SEP initiation codon (red) by determining the molecular 
weight of immunoprecipitated FRAT2-SEP-FLAG using MALDI-MS. (B) This ACG 
was confirmed as the FRAT2-SEP initiation codon by site-directed mutagenesis 
followed by western blots of FRAT2-SEP-FLAG using an anti-FLAG antibody. 
Conversion of the ACG to an ATG resulted in higher expression (lane 2), while 
ablation of this codon removed all expression (lane 3). In addition, perturbation of 
the Kozak sequence (lanes 4-7) revealed the importance of context when using 
non-AUG codons, as substitution of less favorable residues (38) at the most 
important positions in the Kozak sequence resulted in lower FRAT2-SEP-FLAG 
expression. (C) Epitope tagging of the sORF and CDS of the FRAT2 mRNA 
demonstrates that the FRAT2 mRNA is bi-cistronic. Specifically, the FRAT2 CDS 
was c-myc tagged and the FRAT2-SEP was FLAG tagged. Conversion of the 
FRAT2-SEP initiation codon from ACG to ATG ablates the expression of the 
downstream FRAT2-CDS, indicating the importance of alternate start codons for 
polycistronic expression. 
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Remarkably, mutation of the ACG start codon of the FRAT2-SEP to an ATG 
increases FRAT2-SEP expression, but also completely eliminates the expression 
of FRAT2 protein, revealing that the translation of the downstream cistron 
absolutely requires leaky upstream initiation. Therefore, this experiment indicated 
that an upstream non-AUG initiation codon is necessary for efficient polycistronic 
gene expression. 
 
1.13 Measuring the cellular concentrations of SEPs 
As a first step towards exploring the functional potential of the discovered SEPs 
we wished to determine whether they persist in the cell as concentrations that are 
comparable to that of known functional peptides and proteins. We therefore 
measured the cellular concentrations (K562 cells) of three randomly selected 
SEPs (ASNSD1-SEP, PHF19-SEP and H2AFx-SEP) using isotope dilution mass 
spectrometry (58) (Figure 1.11). In these experiments, isotopically heavy-labeled 
peptides corresponding to the detected peptides that were used to identify these 
three SEPs were synthesized and added to the cells during extraction. The 
sample was then processed as described above (Figure 1.1) except that the 
ERLIC fractionation step was omitted. Removal of the ERLIC speeds up the 
sample preparation but also results in less sensitivity during the LC-MS analysis. 
Therefore, we compensated for the loss of ERLIC by using selected ion 
monitoring (SIM) during the LC-MS, which is more sensitive. Analysis of the 
lysate by LC-MS is able to distinguish the light (endogenous) and heavy  
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Figure 1.11 SEP quantification. (A) SEPs were quantified by isotope dilution-
mass spectrometry (IDMS). We synthesized a deuterated (heavy-labeled) variant 
of the diagnostic SEP peptide we detected. Upon isolation of K562 cells this 
peptide was added and the entire mixture was separated using our standard 
approach to isolate SEPs. SEPs are then quantified by LC-MS since the 
deuterated SEP and endogenous SEP can be distinguished by differences in 
their masses. (B) Overlap between the endogenous SEP and the deuterated SEP 
along with (C) matching MS/MS spectra (note: 10 Da shift for heavy peptide for 
some fragments), indicate that these are the same peptides. (D) Quantification of 
several SEPs using this approach.  
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(exogenously added) variants of the SEP, and since a known amount of heavy 
labeled SEP was added, the ratio of light-to-heavy can be used to quantify the 
absolute amount of endogenous peptide. These SEPs were found to have 
concentrations of between 10 and 2000 copies per cell (Figure 1.11D). Thus, 
based on previous estimates of protein copy numbers, SEPs are found at 
concentrations well within the range of that of typical cellular proteins (59-61). We 
further note that the MS/MS spectra from the synthetic standards used in these 
experiments were nearly identical to those produced from the endogenous 
peptide and eluted at the same retention time as same, thus confirming these 
identifications (Figure 1.11C). 
 
1.14  SEPs exhibit sub-cellular localization 
After failing to observe expression of DEDD2-SEP from the full-length DEDD2 
transcript (Figure 1.7), we subcloned an expression construct for FLAG-tagged 
DEDD2-SEP to determine whether the peptide could be stably expressed. 
Interestingly, we found that DEDD2-SEP localizes to mitochondria in HEK293T, 
mouse embryonic fibroblast (MEF), and COS7 cells, as demonstrated by co-
localization with the mitochondrial marker MitoTracker Red (Figure 1.13A-C). 
This finding suggests that DEDD2-SEP may have a role in mitochondrial 
function, which is interesting because the DEDD2 CDS has been implicated in 
apoptosis (62, 63), which is largely dependent on the mitochondria. The N-
terminus of DEDD2-SEP is predicted to contain a mitochondrial import signal  
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Figure 1.12 DEDD2-SEP localizes to the mitochondria. DEDD2-SEP was 
subcloned and expressed in HeLa (A), MEF (B) and COS7 (C) cells to examine 
its expression and localization by immunofluorescence. Co-staining with 
MitoTracker (red) indicated that the DEDD2-SEP localizes to the mitochondria 
(overlay). 
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(64). Sequence-dependent trafficking and sub-cellular localization of SEPs could 
therefore be general phenomena related to their biological activities.  
 
1.15 SEPs participate in protein-protein interactions 
During the analysis of FRAT2-SEP expressed in HEK293T cells (Figure 1.6), we 
observed reproducible co-immunoprecipitation of a higher molecular weight 
protein (Figure 1.14A). This signaled the presence of a potential protein-protein 
interaction partner. Proteomic analysis of this protein band revealed the putative 
FRAT2-SEP binding partner as mitochondrial P32 (P32, HABP or C1QBP) (65). 
We confirmed that this protein-protein interaction occurs in the parent K562 cell 
line (and therefore may occur endogenously) by immunoprecipitation of 
transiently transfected FLAG-tagged FRAT2-SEP. We detected co-
immunoprecipitation of P32 in transfected cells by immunoblotting with an anti-
P32 antibody, with no background in cells transfected with empty vector (Figure 
1.14B). The fact that FRAT2-SEP specifically interacts with another protein is 
highly suggestive that SEPs will be found to have cellular functions. 
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Figure 1.14 FRAT2-SEP participates in a protein-protein interaction with P32. (A) 
A Krypton fluorescent protein stained gel showing a band co-immunoprecipitating 
with FRAT2-SEP-FLAG. This band migrates at approximately 30 kD. Excision of 
this band and proteomic analysis revealed its identity as mitochondrial P32 
(P32). (B) The FRAT2-SEP-P32 interaction was confirmed in K562 cells by 
transient transfection and immunoprecipitation of FRAT2-SEP-FLAG followed by 
immunoblotting with anti-P32 antibody. 
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1.16  SEPs influence gene expression 
The serendipitous discoveries that SEPs participate in protein-protein interactions 
and exhibit subcellular localization piqued our interest in the functional potential 
of these molecules. We wondered whether some SEPs possess other 
bioactivities, such as the ability to influence gene expression. We therefore 
performed gene expression profiling experiments on 10 SEPs. 
 The microarray is the gold standard in global gene expression assays; 
however, this technique is time consuming and expensive. Recently, a group led 
by Aravind Subramanian of the Broad Institute of MIT and Harvard developed a 
high-throughput and highly cost-effective alternative for measuring gene 
expression on a global scale. The method is based on the observation that gene 
expression is highly correlated. By determining the expression levels of a 
carefully selected set of “landmark” genes, this group has found, it is possible to 
accurately infer the expression profile of the remainder of the genome using 
known correlation patterns. Specifically, the assay involves determining the 
mRNA levels of 1000 genes using a ligation-mediated amplification (LMA) 
protocol coupled with Luminex bead technology (66). In the LMA step, 
amplification is accomplished using locus-specific probes containing unique 
molecular barcodes and universal biotinilated primers. Amplified transcripts are 
incubated in streptavidin-phycoetherin, hybridized to optically-addressed beads 
that anneal to specific “barcode” sequences, and analyzed using a two-laser flow 
cytometer, whereby one laser detects the bead color (denoting transcript identity) 
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and the other laser detects phycoetherin fluorescence (indicating transcript 
abundance). 
 To assess the effects of SEPs on gene expression, we used the L1000 
assay to compare the gene expression profiles of two sets of samples: an 
experimental set in which cells (HEK293T) were transfected with an 
overexpression construct containing the sORF encoding the SEP to be studied 
and a control set in which cells were transfected with an overexpression 
construct containing the sORF encoding that SEP but with the start codon 
ablated so no polypeptide would be produced. For each SEP, cells were 
harvested at three time points: 10 hours, 20 hours and 30 hours. Overexpression 
was verified by immunofluoresence imaging (all SEPs were C-terminally FLAG-
tagged). These samples (n=6) were then analyzed by the L1000 assay to 
determine the differential expression pattern of the experimental sample. 
 Six out of the 10 SEPs produced statistically significant signatures (p-
value < 0.05). Of the six SEPs tested, two – C7ORF49-SEP and DNLZ-SEP – 
appeared to produce significant changes in gene expression, as indicated by a 
heat map illustrating the expression differential for the 50 most up-regulated and 
the 50 most down-regulated genes (Figure 1.15). While this result is significant 
because it indicates that these SEPs have biological activity, we wanted to get 
more insight in the nature of the signatures our SEPs produced. For this, we 
turned to a knowledge-based method for analyzing differential gene expression 
data called Gene Set Enrichment Analysis (GSEA) (67).  
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Figure 1.15 Heat map of the expression levels of the 50 most up-regulated 
genes and the 50 most down-regulated genes in the C7ORF49-SEP and DNLZ-
SEP overexpression experiments. Gene expression levels in HEK293T cells in 
which SEP was overexpressed are shown on the left of each diagram. Gene 
expression levels in the control samples (no SEP) are shown on the right of each 
diagram. Red indicates high expression and blue indicates low expression. 
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In GSEA, genes are sorted into a rank-ordered list according to their differential 
expression levels and then a set of genes that is known to be involved in a 
particular pathway is mapped onto the list. The degree to which that gene set is 
enriched in the sample – that is, the degree to which it is overrepresented at the 
top or bottom of the list – is assessed by ʻwalkingʼ down the list and increasing a 
running-sum statistic when a gene in the set is encountered and decreased the 
metric when a gene that is not in the list is encountered. The resulting metric is 
called the enrichment score (ES). When normalized for gene set size, the ES can 
be used to determine whether the perturbagen used in the experiment (in this 
case, a SEP) modulates the gene expression of this set to a degree that would 
indicate the perturbagen targets a regulation pathway that controls the 
expression of the gene set. An NES score whose absolute value is greater than 
2.25 indicates a substantial enrichment of the gene set in question.  
 The GSEA analysis of the expression signature produced by DNLZ-SEP 
indicated that this SEP targets the same gene sets as heat shock factor protein 2 
(HSF2), estrogen receptor beta 2 (ESR2) and transcription factor ETV6 (Table 
1.4). Interestingly, chromosomal aberrations involving ETV6 are found in chronic 
myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML). It is 
therefore conceiveable that this SEP plays a role in producing the disease 
phenotype of the cells used in this study, which are myelogenous leukemia cells.  
C7ORF49-SEP also produced a signature that was enriched with curated gene 
sets, several of which are involved in controlling basic processes in translation 
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(Table 1.5). These results demonstrate that SEPs are capable of modulating 
gene expression on a global scale, and in some cases in a manner similar to that 
of known functional species. 
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Table 1.4 Results of gene set enrichment analysis for DNLS-SEP. The 
normalized enrichment score (NES) indicated the degree to which the SEP up-
regulated genes in the set. A score above 2.25 indicates substantial up-
regulation. Detailed descriptions of the gene sets can be found at 
http://www.broadinstitute.org/cmap/. 
Gene Set NES 
Nominal 
p-value FDR 
HF2506_UP_desc:HSF2 2.61 0 0 
HF1775_UP_desc:ESR2 2.29 0 0 
HF2164_UP_desc:ETV6 2.29 0  0 
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Table 1.5 Results of gene set enrichment analysis for C7ORF49-SEP. The 
normalized enrichment score (NES) indicated the degree to which the SEP up-
regulated genes in the set. A score above 2.25 indicates substantial up-
regulation. Detailed descriptions of the gene sets can be found at 
http://www.broadinstitute.org/cmap/. 
Gene Set NES 
Nominal 
p-value FDR 
REACTOME_60S_RIBOSOMAL_SUBUNIT  5.009  0  0 
REACTOME_FORMATION_OF_40S_SUBUNITS  4.890  0  0 
HSIAO_HOUSEKEEPING_GENES  4.797  0  0 
KEGG_RIBOSOME  4.564  0  0 
KEGG_SPLICEOSOME  3.995  0  0.02 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1.17 Conclusion 
In conclusion, we used a novel approach to discover the largest number of 
human SEPs ever reported. Importantly, we successfully access the pool of 
SEPs that are under 50 amino acids in length, including two peptides that are a 
mere 14 residues long. This is unprecedented for mass spectrometry-based 
discovery approach and is a crucial step towards understanding the biology of 
these molecules; for as we learned from the example of polished rice in 
Drosophila (12), SEPs as small as 11 amino acids can play a significant 
functional roles in animals. Moreover, the smallest SEPs are those least likely to 
be discovered by comparative genomics approaches due the distinctive 
challenge of detecting the evolutionary signature of conservation over short 
protein-coding sequences.   
 We also uncovered several unexpected features of SEPs, among them 
that SEP translation is frequently initiated at non-AUG codons and that SEPs can 
arise from polycistronic mRNAs. Highlighting the interplay between these 
features, we find that the non-AUG start codon of one of our SEPs is necessary 
for efficient polycistronic gene expression. This may explain why such a large 
fraction of the discovered SEPs initiate at non-AUG sites. Lastly, we determined 
that SEPs persist in the cell at concentrations that are comparable to known 
functional proteins. Perhaps most intriguingly, though, we find that SEPs possess 
properties characteristic of functional proteins, such as stable expression, high 
cellular copy numbers, post-translational modifications, subcellular localization, 
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the ability to participate in specific protein-protein interactions and the ability to 
influence gene expression. 
Taken together, these findings indicate that the human proteome is 
significantly more complex than previously appreciated. Moreover, due to the 
bias of mass spectrometry for more abundant species (55), which limits the 
scope of our technique to the most highly expressed or most stable SEPs, it is 
probable that there are many more as-yet-undiscovered human SEPs. Thus, we 
believe we have only begun to explore the breadth and diversity of this exciting 
new family of polypeptides. 
 
 
1.18 Materials and methods 
 
Cloning and mutagenesis 
DNA constructs were prepared by standard ligation, Quikchange, or inverse PCR 
techniques. Human cDNA clones were obtained from Open Biosystems. Gene 
synthesis was by DNA2.0. Plasmid sequences are publicly available at 
http://web.me.com/saghatelian/Saghatelian_Lab/Home.html or upon request. We 
note that the YTHDF3-SEP construct consisted of the 5ʼ-UTR putatively encoding 
the SEP only, obtained via gene synthesis because a full-length cDNA construct 
with an intact 5ʼ-UTR was not commercially available. 
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Cell culture 
Cells were grown at 37ºC under an atmosphere of 5% CO2. HEK293T, HeLa, 
COS7 and MEF cells were grown in high-glucose DMEM supplemented with L-
glutamine, 10% fetal bovine serum, penicillin and streptomycin. K562 cells were 
maintained at a density of 1-10 x 105 cells/mL in RPMI1640 media with 10% fetal 
bovine serum, penicillin and streptomycin. 
 
Isolation and processing of polypeptides 
Aliquots of 3 x 107 growing K562 cells were placed in 1.5 ml Protein LoBind 
Tubes (Eppendorf), washed three times with PBS, pelleted and stored at -80 °C. 
Boiling water (500 μl) was added directly to the frozen cell pellets and the 
samples were then boiled for 20 minutes to eliminate proteolytic activity (20, 21). 
After cooling to room temperature, samples were sonicated on ice for 20 bursts 
at output level 4 with a 40% duty cycle (Branson Sonifier 250; Ultrasonic 
Convertor). The cell lysate was then brought to 0.25% acetic acid by volume and 
centrifuged at 20,000 x g for 20 minutes at 4°C. The supernatant was sent 
through a 30 kD or 10 kD molecular weight cut-off (MWCO) filter (Modified PES 
Centrifugal Filter, VWR). The mix of small proteins and peptides in the flow-
through was evaluated for protein content by BSA assay and then evaporated to 
dryness at low temperature in a SpeedVac. Pellets were re-suspended in 50 μl of 
25mM TCEP in 50mM NH4HCO3 (pH=8) and incubated at 37 °C for 1 hour. The 
reaction was cooled to room temperature before 50 μl of a 50 mM iodoacetamide 
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solution in 50 mM NH4HCO3. This solution was incubated in the dark for 1 hour. 
Samples were then dissolved in a 50 mM NH4HCO3 solution of 20 μg/μl trypsin 
(Promega) to a final protein to enzyme mass ratio of 50:1. This reaction was 
incubated at 37 °C for 16 hours, cooled to room temperature and then quenched 
by adding neat formic acid to 5% by volume. The digested peptide mix was then 
bound to a C18 Sep Pak cartridge (HLB, 1cm3; 30mg, Oasis), washed thoroughly 
with water and eluted with 1:1 acetonitrile/water. The eluate was evaporated to 
dryness at low temperature on a SpeedVac. 
 
Offline electrostatic repulsion-hydrophilic interaction chromatography 
(ERLIC) fractionation of polypeptide fraction 
To simplify the sample and thereby improve detection sensitivity in the 
subsequent LC-MS/MS analysis, we separated the processed peptide mix by 
ERLIC (28, 29). ERLIC was performed using a PolyWax LP column (200 x 2.1 
mm, 5μm, 300Å; PolyLC Inc.) connected to an Agilent Technologies 1200 Series 
HPLC equipped with a degasser and automatic fraction collector. All runs were 
performed at a flow rate of 0.3 ml/min and ultraviolet absorption was measured at 
a wavelength of 210 nm. Forty (30 kD sample) or 25 (10 kD sample) fractions 
were collected over a 70 minute gradient beginning with 0.1% acetic acid in 90% 
acetonitrile (aq.) and ending with 0.1% formic acid in 30% acetonitrile (aq.). The 
fractions were then evaporated to dryness on a SpeedVac and dissolved in 15 μl 
0.1% formic acid (aq.) in preparation for LC-MS/MS analysis. 
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LC-MS/MS analysis. Samples were injected onto a NanoAcquity HPLC 
system (Waters) equipped with a 5 cm x 100 μm capillary trapping column (New 
Objective) packed with 5 um C18 AQUA beads (Waters) and a PicoFrit SELF/P 
analytical column (15 μm tip, 25 cm length, New Objective) packed with 3 μm 
C18 AQUA beads (Waters) and separated over a 90 minute gradient at 200 
nl/min. This HPLC system was online with an LTQ Orbitrap Velos (Thermo 
Scientific) instrument, which collected full MS (dynamic exclusion) and tandem 
MS (Top 20) data over 375-1600 m/z with 60,000 resolving power. 
 
Data processing 
The acquired MS/MS spectra were analyzed with the SEQUEST algorithm using 
a database derived from 6-frame (forward and reverse) translation of RefSeq 
(National Center for Biotechnology Information) mRNA transcripts or 3-frame 
(forward only) translation of a transcriptome assembly generated by Cufflinks 
(Trapnell et al 2010) using RNA-Seq data from the K562 cell line (data 
acquisition described below). The search was performed with the following 
parameters: variable modifications, oxidation (Met), N-acetylation; semitryptic 
requirement; maximum missed cleavages: 2; precursor mass tolerance: 20 ppm; 
and fragment mass tolerance: 0.7 Da. Search results were filtered such that the 
estimated false discovery rate of the remaining results was 1%. The Sf score is 
the final score for protein identification by the Proteomics Browser software 
based on a combination of the preliminary score, the cross-correlation and the 
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differential between the scores for the highest scoring protein and second highest 
scoring protein (34). 
Identified peptides were searched against the Uniprot human protein 
database using a string-searching algorithm. Peptides found to be identical to 
fragments of annotated proteins were eliminated from the SEP candidate pool. 
The remaining peptides were searched against non-redundant protein sequences 
using the Basic Local Alignment Search Tool (BLAST). Any peptides found to be 
less than two amino acids different from the nearest protein match (i.e., identical 
or different by one amino acid) were discarded. 
The spectra of the remaining peptides were subjected to a rigorous 
manual validation procedure: spectra were rejected if they had a precursor mass 
error of >5 ppm, if they lacked a sequence tag of 5 consecutive b- or y-ions, if 
they had more than one missed cleavage, or if they lacked sufficient sequence 
coverage to differentiate from the nearest annotated protein. 
 
RNA-Seq library preparation, alignment, and transcriptome assembly 
Two types of cDNA libraries were generated from K-562 RNA (Ambion). In the 
first experiment, we used 50 nanograms of polyA+ RNA to create standard, non-
strand-specific cDNA libraries with paired-end adaptors as previously described 
(68) and sequenced it on one lane of an Illumina Genome Analyzer IIa machine. 
In the second experiment, we used eight different amounts of total RNA (30 ng, 
100 ng, 250 ng, 500 ng, 1000ng, 3000 ng, and 10,000 ng) to create cDNA 
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libraries with paired-end, indexed adaptors following the instructions for the 
Illumina TruSeq RNA sample prep kit, except that we used SuperScript III instead 
of SuperScript II and optimized PCR cycle number. These libraries were 
sequenced on a single lane of a HiSeq2000 machine. RNA-Seq reads were 
aligned to the human genome (Hg19 assembly) using TopHat [version V1.1.4; 
Trapnell et al. Bioinformatics 2009] and transcriptome assembly was performed 
using Cufflinks [version V1.0.0; (69)]. lincRNAs were called based on a lincRNA-
calling pipeline as previously described (70). The transcriptome data is deposited 
on GEO (GSE34740).  
 
Peptide synthesis, purification and concentration determination 
Automated (PS3 Protein Technology, Inc.) solid-phase peptide synthesis was 
carried out using Fmoc amino acids. Crude peptides were HPLC (Shimadzu)-
purified using a C18 column (150 mm × 20 mm, 10 μm particle size, Higgins 
Analytical). The mobile phase was adjusted for each peptide; buffer A was 99% 
H2O, 1% acetonitrile, and 0.1% TFA; buffer B was 90% acetonitrile, 10% H2O, 
and 0.07% TFA). Pure fractions were identified by MALDI-MS analysis, 
combined, and lyophilized. Peptide concentrations were determined by amino 
acid analysis (AlBio Tech). 
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Absolute quantification of SEPs 
Isotope dilution mass spectrometry (IDMS) (58) was used to determine the 
concentration of SEPs in K562 cells. All samples for this experiment were 
prepared by adding known amounts of heavy isotope-labeled peptides 
corresponding the detected fragment of the SEP of interest to a K562 cell pellet 
(107 cells) just before isolation of the polypeptides from these cells. The 
preparation of these samples was identical to that described above except that 
no ERLIC separation was done. The first step of the quantification procedure was 
to prepare a set of samples where each sample contained a different but known 
amount (1 fmol, 10 fmol, 50 fmol, 100 fmol, 500 fmol, 1 pmol or 10 pmol) of the 
heavy-labeled counterpart peptide. These samples were then analyzed by a 
selected ion monitoring (SIM) method on the previously described LC-MS/MS 
system and the resulting data was analyzed using Xcaliber 2.0 (Thermo 
Scientific). The areas of the peaks corresponding to the endogenous and 
isotope-labeled peptides were compared to determine the approximate 
concentration of the SEP and a standard curve was generated to verify that the 
quantity of the SEP fragment was within the linear range of the mass 
spectrometer. A second set of samples that each contained an amount of 
isotope-labeled peptide that was within the linear range of the instrument and 
within an order of magnitude of the amount of the corresponding endogenous 
peptide in the cells was then prepared (N=4) and analyzed as described. The 
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results of this experiment were used to determine the absolute cellular 
concentration of the selected SEPs. 
 
Imaging SEPs by immunofluorescence  
HeLa, COS7, and MEF cells were grown to 80% confluency on glass coverslips 
in 48-well plates; HEK293T cells were grown to 50-75% confluency on fibronectin 
(Millipore)-coated glass coverslips in 48-well plates. Cells were transfected in 
Opti-MEM (Invitrogen) with 250 ng plasmid DNA using Lipofectamine 2000 
(Invitrogen) according to the manufacturerʼs instructions. 24 hours after 
transfection, cells were fixed with 4% formalin in phosphate buffered saline (PBS) 
for 10 minutes at room temperature, and then permeabilized with methanol at -
20ºC for 10 minutes. Fixed cells were blocked with blocking buffer (3% BSA in 
PBS with 0.5% Tween-20), then incubated overnight at 4ºC with anti-FLAG M2 
antibody (Sigma) diluted 1:1000 in blocking buffer. After washing 3x with PBS, 
cells were then stained for one hour at room temperature with goat anti-mouse 
AlexaFluor 488 conjugate (Invitrogen) diluted 1:1000 in blocking buffer. Cells 
were washed 3x with PBS, post-fixed with 4% formalin for 10 minutes at room 
temperature, then counterstained with a final concentration of 270 ng/mL 
Hoescht 33258 (Invitrogen) in PBS for 15 minutes at room temperature. Cells 
were then imaged in PBS in glass-bottom imaging dishes (Matek Corp.). For 
mitochondrial co-localization analysis, transfected cells were treated with 
MitoTracker Red CMXRos (Invitrogen) at a final concentration of 100 nM in PBS 
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at 37ºC for 15 minutes, washed once with PBS, then fixed with formalin and 
methanol and immunostained as described above. 
Images were acquired in the Harvard Center for Biological Imaging on a 
Zeiss LSM 510 inverted confocal microscope with the following lasers: 405 
Diode, 488 (458,477,514) Argon, 543 HeNe and 633 HeNe. Image acquisition 
was with either AIM or Zen software. Images were acquired with a 60x oil 
immersion objective. 
 
Determination of the FRAT2-SEP start codon by immunoprecipitation and 
MALDI-MS 
COS7 and HEK293T cells were grown in 10-cm dishes to 75% confluency, then 
transfected with 10 µg plasmid DNA using Lipofectamine 2000 according to the 
manufacturerʼs instructions. 24 hours after transfection, cells were harvested by 
scraping and washed 3x with PBS. Cells were lysed in 400 µL Triton lysis buffer 
(1% Triton X-100 in Tris-buffered saline (TBS) with Roche Complete Mini 
Protease Inhibitor added) on ice for 15 minutes, then lysates were clarified by 
centrifugation at 16,100 x g for 20 minutes at 4ºC. Clarified lysates were added to 
50 µL of PBS-washed anti-FLAG M2 agarose resin (Sigma) and rotated at 4ºC 
for 1 hour. Beads were washed 6x with TBS-T (Tris-buffered saline with 0.05% 
Tween-20). To elute bound proteins, 50 uL of 100 ug/mL 3x FLAG peptide 
(Sigma) in TBS-T was added to the resin and rotated at 4ºC for 20 minutes. 
Eluates were stored at -80ºC until further analysis. 
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For MALDI-MS analysis, the entire protein sample was desalted using a 
C18 Sep Pak cartridge (HLB, 1cm3; 30mg, Oasis) and eluted in 50% acetonitrile. 
The sample was dried in a SpeedVac, and then dissolved in a final volume of 10 
µL mass spectrometry-grade water (Burdick & Jackson). This solution (1 µL) was 
mixed with matrix (α-cyano-4-hydroxycinnamic acid in 50% acetonitrile, 1 µL) on 
a stainless steel MALDI plate and air-dried. Data were acquired on a Waters 
MALDI micro MX instrument operated in linear positive mode. Instrument control 
and spectral acquisition were with MassLynx software.  
 
Confirmation of the FRAT2-SEP initiation codon, Kozak sequence, and 
bicistronic expression by immunoblotting  
HEK293T cells were grown to 75% confluency in 6-well plates, then transfected 
with 10 µg plasmid DNA using Lipofectamine 2000 according to the 
manufacturerʼs instructions. Cells were harvested by vigorous pipetting and lysed 
in 100 µL Triton lysis buffer. Samples of clarified lysate (20 µL) were mixed with 
SDS-PAGE loading buffer, boiled, and electrophoresed on 4-20% Tris-HCl gels 
(Bio-Rad). Two replicate gels were run. Proteins were transferred to 
nitrocellulose (0.20 µm pore size, Thermo Scientific) and immunoblots were 
probed with anti-FLAG M2 antibody (Sigma) followed by goat anti-mouse IR dye 
800 conjugate (LICOR). For bicistronic expression assays, immunoblots were 
probed with a mixture of rabbit anti-c-myc antibody (Sigma) and anti-FLAG M2, 
followed by a mixture of goat anti-mouse IR dye 800 and goat anti-rabbit IR dye 
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680 (LICOR). A replica immunoblot was probed with mouse anti-β-actin followed 
by goat anti-mouse IR dye 800. Antibodies were diluted 1:2000 in Rockland 
Immunochemicals fluorescent blocking buffer. Infrared imaging was performed 
on a LICOR Odyssey instrument. 
 
Co-immunoprecipitation, LC-MS proteomics, and immunoblotting to detect 
FRAT2 protein-protein interaction partners 
HEK293T cells were grown in 10-cm dishes to 75% confluency, then transfected 
with 10 µg plasmid DNA using Lipofectamine 2000 according to the 
manufacturerʼs instructions. Cells were harvested, lysed, and subjected to 
immunoprecipitation as described. 
For SDS-PAGE analysis, 20 uL of the eluate was boiled in SDS-PAGE 
loading buffer, then electrophoresed on a 4-20% Tris-HCl gel (Bio-Rad). Gels 
were stained with Coommassie brilliant blue and bands of interest were excised 
with a clean razor blade and subjected to in-gel trypsin digest and LC-MS/MS 
analysis. Proteins were identified using Sequest. 
To confirm P32 binding, HEK293T cells were grown and transfected as 
above, then co-immunoprecipitation with anti-FLAG agarose was performed as 
described. A sample (10 μL) of each eluate was boiled in SDS-PAGE loading 
buffer, then electrophoresed on a 4-20% Tris-HCl gel. Three replicate gels were 
run. Proteins were transferred to nitrocellulose and probed with rabbit anti-
C1QBP antibody (Sigma) followed by goat anti-rabbit IR dye 680 conjugate. A 
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replica immunoblot was probed with anti-FLAG M2 antibody followed by goat 
anti-mouse IR dye 800 conjugate. Antibodies were diluted 1:2000 in Rockland 
Immunochemicals fluorescent blocking buffer. A third replica gel was stained with 
Krypton protein stain (Pierce) to detect total protein loading.  
To confirm P32 binding to FRAT2-SEP in K562 cells, cells were passaged 
to a density of 5 x 105 cells/mL in Opti-MEM (Invitrogen) in 10-cm dishes and 
grown for 24 hours. Once cells reached a density of 1 x 106 cells/mL, 10 µg of 
plasmid DNA was transfected with Lipofectamine according to the manufacturerʼs 
instructions. Cells were harvested 24 hours after transfection by centrifuging for 5 
minutes at 100 x g, washed 3x with PBS, and lysed as described. Co-
immunoprecipitation and immunoblotting were performed as described. 
 
Preparing samples for Luminex 1000 analysis 
HEK293T cells at 75% confluence in 96-well plate wells were transfected as 
described in “Imaging SEPs by immunofluorescence” (n=6). Cells were also 
transfected in 48-well plates in parallel to serve as tests of transfection efficiency 
for each construct employed. At the relevant time point (10, 20 or 30 hours after 
transfection), cells were gently washed 3x with PBS and 100 ul of Buffer TCL 
(Qiagen Inc.) was added. The 48-well plate samples were then prepared and 
imaged as described in “Imaging SEPs by immunofluorescence”. Plates were 
then covered in aluminum foil and gently shaken for 30 minutes to ensure 
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complete lysis. Finally, plates were placed in a -80 C freezer for storage until 
Luminex 1000 analysis could be performed. 
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Chapter 2 
 
Substance P: A Case Study in the Challenges of  
Investigating Bioactive Peptide Regulation 
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2.1 Introduction 
 
Peptides constitute a major class of signaling molecules in animals and have 
been shown to play a role in diverse physiological processes, including glucose 
homeostasis (insulin) (1), hypertension (angiotensin) (2), social behavior 
(oxytocin) (3), appetite (ghrelin) (4) and sleep (orexins) (5-9). As a result, 
elucidating the molecular mechanisms by which bioactive peptides are regulated 
is an interesting and important research endeavor.  
 Protease cleavage is a well-established paradigm for the regulation of 
peptide levels and signaling in vivo, and pharmacologically targeting proteolytic 
pathways that control peptide levels has proven effective in treating human 
disease. For example, angiotensin converting enzyme (ACE) inhibitors, which 
prevent the production of the vasoconstrictor peptide angiotensin II, are 
commonly used to treat hypertension (10). Similarly, dipeptidyl peptidase 4 
(DPP4) inhibitors, which raise insulin levels by preventing the degradation of the 
insulinotropic hormone glucagon-like peptide 1 (GLP1), are a new class of anti-
diabetes drugs (11). However, despite the clear basic and biomedical importance 
of understanding the proteolytic pathways controlling peptide levels in vivo, these 
processes have been defined for only a small fraction of the known bioactive 
peptides.  
 In this chapter, I explore the strategies that have historically been used to 
probe bioactive peptide regulation by examining the case of substance P, which 
was the first bioactive peptide discovered and is probably the most well studied. 
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Understanding the strengths and pitfalls of these methods suggests a path 
towards more efficient and effective studies. In the concluding section, I outline a 
promising new approach that integrates analytical chemistry, classical 
biochemistry and genetic or pharmacological studies in animal models into a 
general platform for defining the biochemical pathways that control the activity of 
bioactive peptides. This powerful method lacks many of the deficiencies of 
traditional approaches and in theory can be readily applied to any bioactive 
peptide. In chapter 5, I discuss a study that brings this method to bear on 
substance P.  
 
2.2 Substance P and its functional role in mammals 
Discovered in 1931, substance P is a bioactive undecapeptide (Figure 2.1) that is 
widely expressed in the central and peripheral nervous systems (12) of mammals 
and functions as a neurotransmitter and neuromodulator (13). It has been shown 
to play a role in such diverse processes as pain transmission (14-16), 
inflammation (17, 18), sleep (19), learning and memory (19-21), depression and 
affective mood disorders (22-24), opioid dependence (25-27) and apoptosis (28, 
29).  
 
 
Arg1-Pro-Lys-Pro-Gln5-Gln-Phe-Phe-Gly-Leu10-Met-NH2 
 
Figure 2.1 The structure of substance P. The mature peptide is amidated at the 
C-terminal. 
 
 
 85 
2.3 Substance P biogenesis, secretion and mechanism of action 
A member of the tachykinin family of neuropeptides, substance P is synthesized 
from the preprotachykinin-A gene into a large, biologically inert protein precursor, 
or prepropeptide (29). Converting enzymes process the prepropeptide to release 
a shorter precursor peptide, which is then packaged into vesicles (30, 31) and 
axonally transported to terminal endings (32). There, proteases and amidating 
enzymes produce the mature, active form of substance P, which can be secreted 
into the synapse to perform its function as a neurotransmitter and 
neuromodulator (32). 
 Mechanistically, substance P elicits its effects by binding to one of three 
G-protein coupled receptors that are specific to the tachykinin peptide family: 
neurokinin 1 (NK1), neurokinin 2 (NK2) or neurokinin 3 (NK3) (33-37). However, it 
has the greatest affinity for NK1 and this is believed to be the primary 
endogenous receptor for the peptide (38, 39). Radiolabelling and mutatgenesis 
studies indicate that the key facet of substance P- NK1 coupling is insertion of the 
hydrophobic sequence at the carboxy-terminus of substance P (GLM-NH2) into a 
hydrophobic binding pocket on NK1 (40). The fact that SP(6-11) is the smallest 
fragment of the peptide that retains significant affinity for NK1 underscores the 
importance of the C-terminal region for effective binding (41).  Upon stimulation 
by substance P, NK1 transmits signals into the cell through one or more of three 
second-messenger systems: phosphatidyl inositol stimulation via phospholipase 
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C, which leads to Ca2+ influx (42-44); arachidonic acid release via phospholipase 
A2 (43, 45); or cAMP mobilization via adenylate cyclase(44, 46, 47). 
 
2.4 Substance P inactivation 
Although there is evidence that some fraction of substance P is degraded within 
the endosome after the clathrin-mediated endocytosis that can occur after 
substance P- NK1 binding (48), the majority of secreted substance P is not taken 
back up by the cell but rather is inactivated or converted to other active forms by 
proteolytic cleavage in the intercellular space (49). Several enzymes have been 
suggested to participate in substance P metabolism. Dipeptidyl aminopeptidase 
IV (DPP4) and prolyl endopeptidase (PREP), for example, have been shown to 
degrade Substance P from the N-terminus in vitro (50-52). These enzymes 
produce the C-terminal fragments SP(3-11) and SP(5-11). Additional evidence 
supporting PREP as a Substance P-regulating enzyme is the finding that PREP 
inhibition slightly increases substance P levels in the brain (53, 54). DPP4, on the 
other hand, is virtually absent from the brain, making it an unlikely candidate for 
regulating substance P in the central nervous system.  
 Other enzymes have been found to cleave substance P at the C-terminus 
or exhibit an endopeptidase activity. Angiotensin converting enzyme (ACE), 
which co-localizes with substance P in some regions of the brain (55-58), 
releases substance P fragments SP(1-7) and SP(1-8) when incubated with full-
length peptide (56). Neutral endopeptidase 24.11 (NEP), another co-localizing 
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enzyme (59), cleaves the peptide after Gln6, Phe7 and Gly9 (60, 61). Further 
implicating ACE and NEP in substance P metabolism is the fact that inhibitors of 
these enzymes suppress substance P-degrading activity in brain tissue lysates 
(62, 63). However, more recent studies have revealed that some potent inhibitors 
of ACE and NEP fail to protect substance P from degradation, indicating the 
previous results were due to off-target effects and making it unlikely that these 
enzymes participate in endogenous substance P metabolism (64). Moreover, 
none of the aforementioned enzymes displays a strong specificity for substance 
P and, notably, most are known to act on a variety of other neuropeptides (65).  
In addition to these well-characterized enzymes, several peptidases 
exhibiting a high specificity for substance P have been reported. One such 
enzyme, isolated from the membrane fraction of human brain, hydrolyzed 
substance P at the Gln6-Phe7, Phe7-Phe8 and Phe8-Gly9 bonds and was 
described as a neutral metalloendopeptidase with a molecular weight of 40-
50kDa (66). An approximately 70kD enzyme possessing a very similar activity 
and specificity for substance P was isolated from rat substance Pinal cord and 
given the name substance P-degrading enzyme (SPDE) (66, 67). Another 
substance P-specific enzyme was found in human cerebrospinal fluid and given 
the name substance P endopeptidase (SPE) (52). It cleaved substance P at the 
Phe7-Phe8 and Phe8-Gly9 bonds. Subsequently, enzymes closely resembling 
SPE in affinity for substance P, cleavage pattern and inhibitor sensitivity were 
purified from human spinal cord (68), rat spinal cord (69) and rat brain ventral 
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tegemental area (70). However, the genes from which these substance P-specific 
enzymes derive remain unknown, making rigorous study of their impact on 
endogenous substance P metabolism difficult.  
 
2.5 In vitro approaches to studying substance P degradation 
Ultimately, identifying the enzymes responsible for degrading substance P may 
depend on determining which fragments of the peptide are actually products of 
endogenous metabolism; certainly, such information will accelerate the 
identification process. To this end, many researchers have conducted in vitro 
experiments where cell lysates are incubated with synthetic peptide (52, 71-73) 
or pseudo-in vivo experiments where synthetic peptide is injected into tissues  
(64, 74-76). In these studies, a multitude of fragments have been detected: SP(1-
2), SP(1-4), SP(1-7), SP(1-8), SP(1–9), SP(1-10), SP(4–8), SP(6–10), SP(7–10), 
SP(3–11), SP(5–11), SP(6–11), SP(7–11), SP(8–11). Strong evidence suggests 
a physiological role for SP(1-7) (26, 77-80), establishing the peptide as a likely 
product of endogenous substance P metabolism. Of the remaining fragments, 
some, for example SP(1-4), SP(1-8), SP(1-9) and SP(5-11), have also been 
reported to possess biological activity (15, 81-83), though it is not clear whether 
these have a natural function or whether their activity is simply ʻaccidentalʼ due to 
chemical similarity with the parent peptide.  
These fragments and others could be the final products of inactivation 
cuts, intermediates in conversion pathways, or perhaps independently functioning 
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species. It is also possible, however, that many of the detected fragments result 
from non-specific peptidase activity present in the homogenate or injected tissue 
but which does not participate in natural substance P-degrading pathways. 
Indeed, whenever exogenous peptide is used in a metabolic study, one cannot 
be sure the results are reflective of endogenous metabolism. Additionally, there is 
the confounding factor of location. Substance P is expressed extensively in the 
nervous system, and several of its biological functions seem to be organ-specific 
(84). Thus, insights gleaned from examination of the hypothalamus may not be 
relevant to metabolism at nerve endings in the gut, and results from whole brain 
homogenates or CSF may conflate the metabolism of multiple tissues. In light of 
these considerations, I think it is apparent that a fast, effective approach to 
elucidating the regulation of substance P must include in vivo measurements of 
peptide levels in the tissue of interest and seek to draw candidate peptidases 
from the pool of enzymes known to be present and active in that tissue. 
 
2.6 In vivo approaches to studying substance P degradation 
Overall, the approaches taken to studying substance P metabolism reflect the 
approaches taken to studying bioactive peptide regulation in general. Much work 
aimed at identifying the metabolites of bioactive peptides has relied on in vitro 
experiments, which have the limitations discussed above. Some researchers, 
though, have used in vivo peptide measurements to inform their efforts, and this 
has led to successful identification of the acting peptidases. For example, the 
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discovery of DPP4 as a GLP-1 degrading enzyme (85) relied on an approach that 
combined HPLC fractionation with radioimmunoassay (RIA) to detect 
endogenous metabolites of GLP-1 in blood plasma (86) (87).  
 Despite the evident effectiveness of RIA and other immunoassays (e.g., 
ELISA, EIA) at detecting small quantities of peptide, these methods have some 
significant drawbacks. The potential for antibody cross-reactivity, for example, 
means these assays are not necessarily selective, and the possibility that 
antibodies will not sufficiently react with all possible metabolites – or not react at 
all with metabolites that have undergone modification (i.e., oxidation) – means 
these assays are not necessarily thorough (76, 88). Furthermore, the need for 
specialized reagents (antibodies) makes these methods difficult to incorporate 
into an efficient, general approach to studying bioactive peptide metabolism.  
 
2.7 Conclusion 
In contrast to the techniques discussed above, a mass spectrometry-based 
peptidomics strategy (53, 89-92) could provide detailed information on the in vivo 
metabolism of a bioactive peptide without the disadvantages of immunoassays 
and, importantly, could be readily applied to any bioactive peptide of interest. 
Coupling this technique with in vitro biochemical assays, an enzyme 
purification/identification workflow and a genetic strategy to test for biological 
relevance would create a powerful platform for proteolytic pathway discovery. 
Indeed, such an approach has already been used to characterize the metabolism 
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of peptide histidine isolucine (PHI), a bioactive peptide that promotes glucose-
stimulated insulin secretion, in the intestine (93). In Chapter 5, I describe a study 
in which a customized version of this method was applied to substance P 
regulation in the spinal cord. 
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Elucidating Substance P Regulation in the Spinal Cord 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dr. Arthur Tinoco and I performed the peptidomics experiments, the cross-linking 
experiments and the inhibitor injection experiments. Dr. Arthur Tinoco performed 
the inhibitor screens. I synthesized and purified the peptides and performed the 
in vitro degradation assays. 
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3.1 Introduction 
Substance P is an 11-amino acid bioactive peptide that functions as a 
neurotransmitter in the mammalian nervous system (1). It is one of the most 
widely studied bioactive peptides and has been shown to participate in a variety 
of biological processes, including pain transmission (2-4), inflammation (5, 6) and 
depression (7-9). However, despite the effort that has gone into uncovering the 
biology of substance P, neither the molecular pathways that control its activity nor 
the enzymes that drive them have been definitively identified2.  
 Historically, investigations of bioactive peptide metabolism have relied on 
in vitro experiments to glean insights into endogenous degradation pathways. 
While these experiments can be very informative, they are also difficult to 
interpret because the cellular environment in which the endogenous peptide-
peptidase interactions occur may not be perfectly reconstituted in the test tube. 
Our lab has developed a general approach to elucidating bioactive peptide 
metabolism that we believe circumvents this challenge. By incorporating LC-
MS/MS-based peptidomics experiments into our core workflow, we achieve a 
view directly into the in vivo metabolism of the peptide and can thereby identify 
physiologically relevant metabolites. Subsequent in vitro studies can then be 
used to tease apart the molecular pathways that generate these products.  
                                                
2 Inhibition of prolyl endopeptidase (PREP), which acts on the N-terminus of 
substance P to produce SP(3-11) and SP(5-11) , slightly increases substance P 
levels in the brain (11, 12), which suggests that the enzyme may degrade 
substance P in vivo. However, because SP(3-11) and SP(5-11) are both very 
good agonists for the primary substance P receptor neurokinin 1, it is unlikely that 
PREP is the primary inactivator of substance P in vivo.  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 Our laboratory recently demonstrated the effectiveness of this approach 
by characterizing the intestinal metabolism of peptide histidine isolucine (PHI), a 
hormone that promotes glucose-stimulated insulin secretion (13). Here I describe 
a study in which we brought such an approach to bear on substance P 
metabolism in the spinal cord. Specifically, we harnessed our laboratoryʼs in vivo 
peptidomics expertise to identify two physiological relevant metabolites of 
substance P in the spinal cord: the N-termial fragments SP(1-9) and SP(1-7). 
Focusing our efforts on the SP(1-9)-producing pathway, we then utilized in vitro 
biochemical assays to identify a GM6001-sensitive activity that generate SP(1-9) 
from substance P and a GM6001-sensitive activity that constitutes a majority of 
the total substance P-degrading activity in spinal cord. Finally, we determine that 
GM6001 treatment causes a nearly three-fold increase in endogenous substance 
P levels in the spinal cord. This is the largest change in substance P levels ever 
induced by a genetic or pharmacological strategy and indicates that GM6001 
blocks a pathway that controls the endogenous levels of substance P in the 
spinal cord. 
 
3.2 Quantitative in vivo peptidomics analysis of mouse spinal cord to 
identify physiological metabolites of substance P 
Our first goal was to identify physiologically relevant substance P degradation 
fragments. To achieve this, we extracted the mouse spinal cord peptidome using 
an LC-MS/MS-based peptidomics platform that our laboratory had previously 
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developed (11, 14, 15). We detected only full-length substance P and the N-
terminal fragments SP(1-9) and SP(1-7) (Figure 3.1). Subsequent isotope dilution 
mass spectrometry (IDMS) experiments determined that the in vivo concentration 
of substance P, SP(1-9) and SP(1-7) were 105.86 ± 8.53 pmol/g, 2.07 ± 0.48 
pmol/g and 1.63 ± 0.50 pmol/g, respectively (Table 3.1). The quantity of the full-
length peptide is comparable to the amount found in rat spinal cord (16). While 
these results do not rule out the possibility that other substance P fragments are 
present in vivo, they do indicate that SP(1-9) and SP(1-7) are endogenous 
substance P metabolites. 
 There are two simple pathway models that could explain our in vivo 
observations. In one model, SP(1-9) and SP(1-7) are produced by independent 
pathways (Figure 3.2A). In the other, SP(1-9) and SP(1-7) are produced 
sequentially in a single pathway (Figure 3.2B). The metabolic step from 
substance P to SP(1-9) takes place in both models and we know from previous 
studies that this step would amount to an inactivation substance P, as the SP(1-
9) fragment does not bind to the substance P receptor NK1 (17, 18). We therefore 
decided to focus our efforts on understanding the substance P to SP(1-9) 
pathway.  
 
 
 
 
 
 
 107 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 Quantitative in vivo peptidomics analysis of mouse spinal cord. 
Substance P (A) and all detectable metabolites (B and C) were quantified by 
isotope dilution-mass spectrometry (IDMS). We synthesized deuterated (heavy-
labeled) variants of the peptides in question and added known quantities of same 
to mouse spinal cord prior to our peptidomics analysis. The peptides are then 
quantified by LC-MS; the deuterated SEP and endogenous SEP can be 
distinguished by differences in their masses. 
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Figure 3.1 (Continued) 
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Figure 3.1 (Continued) 
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Figure 3.1 (Continued) 
 
 
 
 
 
 
 
 
 
 
 
 
0
2000
4000
6000
8000
10000
12000
14000
16000
10
0
10
1
10
2
10
3
10
4
10
5
10
6
10
7
10
8
10
9
11
0
11
1
11
2
In
te
ns
ity

Retention Time (minutes)
deuterated SP(1-7)
endogenous SP(1-7)
 111 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.2 Concentrations of substance P, SP(1-9) and SP(1-7) in mouse spinal 
cord. 
Peptide Concentration (pmol/g) 
Substance P 105.86 ± 8.53 
SP(1-9) 2.07 ± 0.48 
SP(1-7) 1.63 ± 0.50 
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Figure 3.2 Possible substance P degradation pathways. (A) SP(1-9) and SP(1-7) 
are produced by independent pathways. (B) SP(1-9) and SP(1-7) are produced 
sequentially in a single pathway. Intermediates not shown here could exist. 
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3.3 In vitro degradation assay with mouse spinal cord lysate  
We next performed an in vitro biochemical assay to determine whether the 
enzymes responsible for producing these fragments are present in the spinal 
cord (it is otherwise possible that the full length peptide is processed elsewhere 
and the metabolites then transported to the spinal cord). In this experiment, we 
incubated the soluble and insoluble fractions of mouse spinal cord lysate with 
synthetic substance P peptide and then analyzed the quenched reactions by 
matrix assisted-laser desorption ionization (MALDI)-time of flight (TOF)-MS. The 
sensitivity of this instrument is such that we will only observe peptide fragments 
produced from degradation of the exogenous peptide, which is added at a 
quantity well above the detection limit, and not fragments produced by 
endogenous metabolism. We observed that the insoluble fraction of the lysate 
produced SP(1-10), SP(1-9), SP(1-8), and SP(1-7) (Figure 3.3A) whereas the 
soluble fraction did not produce detectable amounts of any N-terminal fragment 
peptide (Figure 3.3B). This indicates that there is enzyme activity present in the 
spinal cord capable of producing the fragments we detect in vivo and that a 
membrane or membrane-bound enzyme is responsible for the activity, which is 
expected given that substance P is degraded in the extracellular space. 
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Figure 3.3 In vitro experiment with either the (A) insoluble or (B) soluble fraction 
of mouse spinal cord lysate. Lysate (1 mg/ml total protein) was incubated with 
substance P (100 uM) for 1 hour at 37 C. (A) Substance P degrading activity in 
the insoluble fraction is competent to produce SP(1-10), SP(1-9), SP(1-8), and 
SP(1-7). (B) No N-terminal substance P fragments were detected in the soluble 
experiment. 
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Figure 3.3 (Continued) 
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Figure 3.3 (Continued) 
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3.4 Assembling a candidate enzyme list from the MEROPS database 
The MEROPS database is an authoritative catalogue of all known peptidases 
and includes detailed information on each peptidaseʼs specificity (19). Because 
substance P is extremely stable in solution and is also very widely studied, it is 
one of the standard substrates used in specificity assays in studies aimed at 
biochemically characterizing a peptidase. Thus, it is likely that most if not all of 
the known peptidases that are capable of cleaving substance P are known to be 
capable of cleaving substance P. We therefore thought that a list of enzymes 
annotated in MEROPS to be capable of cleaving substance P at the Gly9-Leu10 
amide bond would be a good initial candidate list of enzymes that could be 
responsible for the endogenous SP(1-9) producing activity. If the enzyme 
responsible for the activity were already characterized, starting from this 
approach would decrease the time to discovery because it is easier to eliminate 
candidates using inhibitor-based approaches than to make positive identifications 
in an unbiased search for an enzyme. Moreover, given the numerous annotated 
peptidases that have been put forth as endogenous substance P degrading 
enzymes (20-28), determining that a non-annotated enzyme drove a substance 
P-degradation pathway would be a significant result in itself.  
 A search of the MEROPS database revealed that a total of nine 
mammalian peptidases are capable of cleaving substance P to produce SP(1-9) 
(Figure 3.4). We reduced this list to a candidate set of seven by eliminating 
enzymes that had extremely low abundance or else were not present in the  
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Figure 3.4 Assembling a candidate list SP(1-9)-producing enzymes using 
compendiums of peptidase information. A search of the MEROPS database 
revealed that a total of nine mammalian peptidases are capable of cleaving 
substance P to produce SP(1-9). We reduced this list to a candidate set of five by 
eliminating enzymes that had extremely low abundance or else were not present 
in the spinal cord as indicated in the Allen Mouse Spinal Cord Atlas (29) or the 
NEXTBIO Research Database (http://www.nextbio.com/b/nextbio.nb). 
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spinal cord (29). Of these seven enzymes, one (pitrilysin) was annotated as not 
being a membrane or membrane-bound protein. We decided to keep this enzyme 
in our candidate list despite the fact that the SP(1-9)-producing activity is present 
in the insoluble fraction of mouse spinal cord lysate because we thought it 
possible that pitrilysin could be membrane associated despite the annotation. 
  
3.5 Class-specific protease inhibitor screening to identify candidate 
enzyme class 
To determine the class of the peptidase responsible for the SP(1-9)-producing 
activity, we incubated the insoluble fraction of mouse spinal cord lysate (1 mg/ml 
total protein concentration) with synthetic substance P (100 uM) in the presence 
of a battery of class-specific protease inhibitors. We found that the activity was 
sensitive only to metallopeptidase inhibitors and in particular to the zinc chelator 
O-phenanthroline (Figure 3.5B). This finding is consistent with our candidate list 
containing the true SP(1-9)-producing enzyme, as every enzyme in the list is a 
metallopeptidase.  
 Interestingly, in addition to blocking the formation of SP(1-9), this inhibitor 
significantly reduces the degradation of substance P, which suggests it is 
blocking a major degradation pathway. We also observe that o-phenanthroline 
completely eliminates SP(1-7) formation (Figure 3.5A). However, we cannot be 
certain that this is due to a reduction in the levels of SP(1-9) since it is possible 
that GM6001 is inhibiting another enzyme that drives an alternative SP(1-7) 
pathway (i.e., not an SP(1-9) to SP(1-7) pathway). This is consistent with SP(1-9)  
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Figure 3.5 Sensitivity of substance P-degrading activity to class-specific 
peptidase inhibitors. Metallopeptidase inhibitor o-phenanthroline blocks the 
formation of (A) SP(1-7) and (B) SP(1-9) while significantly reducing substance P 
degradation (C). In the case of substance P degradation and SP(1-9) formation, 
o-phenanthroline has a much greater effect than any other inhibitor. In (A) and 
(B), the vertical axis is normalized to the heat untreated sample. In (C), the 
vertical axis is normalized relative to the heat-treated sample. 
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and SP(1-7) being the products of a single pathway. Pepstatin A, which is an 
aspartylpeptidase inhibitor, and PMSF and DMF, which are serine peptidase 
inhibitors, also abolish SP(1-7) formation, which suggest that there are multiple  
SP(1-7)-producing activities present in the spinal cord. 
 
3.6 Enzyme-specific protease inhibitor screening to evaluate candidate 
enzymes 
To determine whether any of the enzymes in our candidate list were responsible 
for the SP(1-9)-producing activity, we incubated the insoluble fraction of mouse 
spinal cord lysate (1 mg/ml total protein concentration) with synthetic substance 
P (100 uM) in the presence of a battery of class-specific protease inhibitors. For 
each candidate enzyme, we included in the survey at least one inhibitor that is 
capable of inhibiting that enzyme and not capable of inhibiting any other 
candidate enzyme (with exception of NEP and ECE-2; neither of these enzymes 
is sensitive to an inhibitor that does not inhibit the other enzyme so we used 
phosphoramidon, which is a potent inhibitor of both enzymes).  
 We found that GM6001, which inhibits enzymes in the neprilysin and MMP 
families, substantially prevents degradation of substance P, with peptide levels 
being over 2-fold higher in the treated sample than in the control. No other 
inhibitors substantially prevented substance P degradation (Figure 3.6C). 
Moreover, GM6001 completely blocks formation of SP(1-9), which reinforces the 
link between substance P levels and the SP(1-9) pathway (Figure 3.6 B).  
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Figure 3.6 Sensitivity of substance P-degrading activity to enzyme-specific 
peptidase inhibitors. Inhibitor-enzyme pairs: SM-19712 (ECE1), phosphoramidon 
(neprilysin; ECE2), MMP9 inhibitor, TIMP2 (MMP inhibitor), GM6001 (MMP and 
neprilysin broad inhibitor), chymostatin (pitrilysin), captopril (ACE), enalaprilat 
(ACE), actinonin (Meprin 1A), and vehicle (PBS with DMSO for 5% DMSO final 
concentration in reaction). MMP and neprilysin family inhibitor GM6001 blocks 
the formation of (A) SP(1-7) and (B) SP(1-9) while significantly reducing 
substance P degradation (C). In the case of substance P degradation and SP(1-
9) formation, GM6001 has a much greater effect than any other inhibitor. In (A) 
and (B), the vertical axis is normalized to the heat untreated sample. In (C), the 
vertical axis is normalized relative to the heat-treated sample. 
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Figure 3.6 (Continued) 
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 Phosphoramidon, which inhibits neprilysin and ECE-2, and chymostatin, 
which inhibits pitrilysin, also prevent SP(1-9) formation to an appreciable degree, 
though not nearly to the extent that GM6001 does (Figure 3.6B). This could be 
due to cross inhibition of a single enzyme by GM6001, phosphoramidon and 
chymostatin, where the latter two are weaker inhibitors for the enzyme. This 
possibility seems especially plausible in the case of GM6001 and 
phosphoramidon considering that both inhibitors target M13 family peptidases.  
 Alternatively, there could be more than one pathway producing SP(1-9) 
involving NEP, pitrilysin or both. In either case, however, the GM6001-inhibited 
enzyme appears to be responsible for the primary SP(1-9)-producing activity and 
has by far the most significant impact on overall substance P levels of the 
inhibitors tested. We therefore eliminate NEP, ECE-2 and pitrilysin as candidates 
for the primary SP(1-9)-producing enzyme. We also eliminate MMP8, MMP9, 
ECE-1 or ACE because no significant change in substance P levels or SP(1-9) 
levels was observed for the reactions in which inhibitors to these enzymes were 
used. 
 
3.7 Wild type vs NEP-/- comparative study  
Prompted by the inconclusive results of the inhibitor survey with regard to NEP, 
we wished to explore the possibility that NEP is involved in substance P 
metabolism, either by driving the SP(1-9) pathway or otherwise. We therefore 
compared the substance P-degrading properties of wild type mouse spinal cord 
tissue with that of lysate from the spinal cords of mice lacking the neprilysin gene 
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(NEP-/-) using our in vitro assay. We found that there was no difference in overall 
subtstance P levels between the reactions and only a negligible difference in 
SP(1-9) levels, indicating that NEP is not responsible for the SP(1-9)-producing 
activity we had observed (Figure 3.7A).  
 We wished to confirm that NEP was not responsible for controlling 
substance P levels in vivo so we used IDMS to quantify the levels of substance P 
in wild type and NEP-/-. We determined that substance P levels in the spinal cord 
are identical in wild type and NEP-/- mice (Figure 3.7B) and conclude that NEP is 
not involved in controlling substance P levels in the spinal cord. 
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Figure 3.7 Comparison of substance P-degrading activity of wild type and NEP-/- 
mouse spinal cords: (A) in vitro and (B) in vivo. (A) There is a very small (~5%) 
difference in overall substance P-degrading activity between the wild type and 
NEP-/- spinal cord lysates (lower panel), indicating that NEP activity does not 
constitute a significant fraction of the total substance P-degrading activity in the 
spinal cord. SP(1-9) and SP(1-7) formation are reduced by approximately 20% 
and 40%, respectively, indicating that NEP contributes to the formation of these 
products in the in vitro assay. (B) Substance P levels in the spinal cord are 
identical in wild type and NEP-/- mice, indicating that NEP is not involved in 
controlling substance P levels in the spinal cord. 
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3.8 Cross-linking experiments using activity-based probes reveals that two 
enzymes may be responsible for the GM6001-sensitive activity 
It is possible that more than one enzyme is responsible for the GM6001-sensitvie 
substance P-degrading activity that we observe in the spinal cord. To get a better 
sense of the number of enzymes that could be involved and get information 
about their respective size, we performed a competitive cross-linking experiment 
with a rhodamine-tagged hydroxamate benzophenone probe (HxBp-RH) that is 
derived from and has the same metal-binding moiety as GM6001 (30). In this 
experiment, spinal cord lysates were mixed with 100 nM of HxBP-Rh in the 
presence or absence of 100 μM GM6001 and then irradiated at 365 nm for 1 
hour to induce cross-linking with the Bp structure of the label. In the samples in 
which it is present, GM6001 will outcompete HxBP-Rh at sites where it 
specifically binds and thus prevent fluorescence of enzymes that had been bound 
to HxBP-Rh in the GM6001-less sample. Thus, bands that fluoresce in the 
absence of GM6001 but disappear when it is added represent GM6001-binding 
proteins.  
 We observe that two proteins, one of molecular weight 100 kDa and the 
other of molecular weight 80 kDa, are bound by GM6001 (Figure 3.8). These 
enzymes could be responsible for the GM6001-inhibited substance P-degrading 
activity we observe. Of the remaining candidate enzymes, only ECE-2, which has 
a molecular weight of 100 kDa, could potentially be one of the proteins observed 
in the experiment. However, considering that the potent ECE-2 inhibitor  
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Figure 3.8 Determining the number and size of proteins responsible for the 
GM6001-sensitive substance P-degrading activity. We performed a competitive 
cross-linking experiment with a rhodamine-tagged hydroxamate benzophenone 
probe (HxBp-RH) that is derived from and has a nearly identical reactivity profile 
to GM6001 (30). Spinal cord lysates were mixed with 100 nM of HxBP-Rh in the 
presence (first two lanes from right) or absence (third and fourth lanes from right) 
of 100 μM GM6001 and then irradiated at 365 nm for 1 hour to induce 
fluorescence. A control was performed in the absence of GM6001 and no 
irradiation (first two lanes from left after ladder). In the samples in which it is 
present, GM6001 will outcompete HxBP-Rh and thus prevent fluorescence of 
enzymes that had been bound to HxBP-Rh in the GM6001-less sample. Thus, 
bands that fluoresce in the absence of GM6001 but disappear when it is added 
represent GM6001-binding proteins. We observe that two proteins, one of 
molecular weight 100 kDa and the other of molecular weight 80 kDa, are bound 
by GM6001 (Figure 3.8) and thus could be responsible for the GM6001-sensitive 
activity.  
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phosphoramidon does not significantly reduce the substance P-degrading activity 
we observe, if the 100 kDa band does correspond to ECE-2, then it is likely that 
only one enzyme – the 80 kDa protein - is responsible for the substance P-
degrading activity we observe. As all of the enzymes known to cleave substance 
P to produce SP(1-9) have been ruled out as candidates, it is likely that this 80 
kDa protein is a novel substance P-degrading enzyme. 
 
3.9 Treatment with GM6001 significantly alters endogenous substance P 
levels 
To determine whether the GM6001-sensitive substance P-degrading activity we 
were observing in our in vitro experiments was involved in controlling substance 
P levels in vivo, we injected 3-4 month old wild type mice with GM6001 to a 
concentration of 100mg of inhibitor to 1 kg of mouse (n=4). After 3 hours, the 
mice were sacrificed and the concentration of substance P in their spinal cords 
was determined by isotope dilution mass spectrometry. The substance P levels 
were nearly 2.73 times higher in the treated mice (Figure 3.9), indicating that 
GM6001 blocks a pathway that controls substance P levels in the spinal cord. 
This is the largest change in endogenous substance P levels that has even been 
induced, pharmacologically or genetically. 
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Figure 3.9 Measuring the impact of GM6001 treatment on substance P levels in 
the spinal cord. GM6001 was injected into 3-4 month old wild type mice to a 
concentration of 100mg of inhibitor to 1 kg of mouse (n=4). After 3 hours, the 
mice were sacrificed and the concentration us substance P in their spinal cords 
was determined by isotope dilution mass spectrometry. The substance P levels 
were nearly 2.73 times higher in treated mice than in untreated mice, which 
indicates that GM6001 blocks a pathway that controls substance P levels in the 
spinal cord. (“**” indicates a p-value of less than 0.01.) 
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3.10 Conclusion 
In this study, we used an LC-MS/MS peptidomics technique to identify two 
physiologically relevant metabolites of substance P in the spinal cord: the N-
termial fragments SP(1-9) and SP(1-7). Focusing our efforts on the pathway that 
produces SP(1-9), we then used in vitro biochemical assays to identify one or 
more GM6001-sensitive activities that generate SP(1-9) from substance P and, 
further, constitute a significant fraction of the total substance P-degrading activity 
in spinal cord lysate. With a competitive cross-linking strategy featuring a 
GM6001-like fluorescent probe, we find that two proteins, one of which is 100 
kDa and other of which is 80 kDa, may be involved in producing this activity. We 
also determine that none of the enzymes currently known to cleave substance P 
to produce SP(1-9) are involved.  
Significantly, we also find that GM6001 treatment causes a nearly three-
fold increase in endogenous substance P levels in the spinal cord. This is the 
largest change in substance P levels ever induced by a genetic or 
pharmacological strategy and indicates that GM6001 blocks a pathway that 
controls the endogenous levels of substance P in the spinal cord. GM6001 can 
therefore be used as an experimental tool to modulate substance P levels in an 
animal model, which could be useful in studies of conditions in which substance 
P levels are speculated to be raised, such as chronic pain and inflammation.  
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3.11 Materials and methods 
 
Compounds  
Mouse substance P was purchased from Anaspec, Inc. A protease inhibitor 
panel was obtained from Sigma Aldrich Inc. 
 
Peptide synthesis  
Heavy-labeled SP(1-7) (Pro containing five 13C and one 15N), SP(1-9) (Phe 
containing eight 2H),  and substance P (Leu containing ten 2H) were synthesized 
manually using FMOC chemistry for solid-phase peptide synthesis. Crude 
peptides were purified by RP-HPLC (Shimadzu) using a C18 column (150 × 20 
mm, 10 μm particle size, Higgins Analytical). The HPLC gradient varied 
depending on the peptide (Mobile Phase A: 99% H2O, 1% Acetonitrile, 0.1% 
TFA; Mobile Phase B: 90% Acetonitrile, 10% H2O, 0.07% TFA). HPLC fractions 
were analyzed for purity by MALDI-TOF (Waters) using α-cyano-4-
hydroxycinnamic acid as the matrix. Pure fractions were combined and 
lyophilized. Concentrations of the purified peptides were determined by UV-vis 
using the extinction coefficient for Phe. 
 
Animal studies 
Wild type (C57BL/6) mice used in this study were either purchased (Jackson 
Labs) or taken from a breeding colony. Nep–/– mice were obtained from Craig 
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Gerard at Childrenʼs Hospital (Boston, MA) and were on a C57BL/6 background. 
Mice in these studies were not littermates from het x het crosses, but were 
obtained from separate colonies of Nep–/– and WT mice. All mice used in this 
study ranged from 3 to 6 months old. Animals were kept on a 12-h light, 12-h 
dark schedule and fed ad libitum. For spinal cord tissue collection, animals were 
euthanized with CO2, their tissue dissected, flash frozen with liquid N2, and stored 
at -80 °C. All animal care and use procedures were in strict accordance with the 
standing committee on the use of animals in research and teaching at Harvard 
University and the National Institute of Health guidelines for the humane 
treatment of laboratory animals. 
 
Isolation of physiological peptides from tissue 
Tissue peptide isolation and fractionation were previously described (15, 31). 
Briefly, frozen spinal cords were placed in 500 µL of water and boiled for 10 
minutes to inactivate any residual proteolytic activity prior to tissue 
homogenization. The aqueous fraction was separated and saved, and the tissue 
was dounce-homogenized in ice-cold 0.25% aqueous acetic acid. The aqueous 
fraction and the homogenate were combined and centrifuged at 20,000 x g for 20 
min at 4 °C. The supernatant was then sent through a 10 kDa molecular weight 
cut-off filter (VWR Modified PES) to enrich the peptide pool and then a C18 Sep 
Pak cartridge (HLB 1cc; 30 mg, Oasis) to desalt the sample. The peptides were 
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then eluted with 1 mL of 70:30 H2O/ACN and concentrated under vacuum using a 
speed vac prior to fractionation by strong cation exchange (SCX).  
 SCX was performed using a PolySULFOETHYL ATM column (200 x 
2.1mm, 5 µm, 300 Å; PolyLC INC.) connected to an Agilent Technologies 1200 
series LC. All runs were operated at 0.3 mL/min. The SCX buffers (prepared with 
MS quality water) consisted of: A) 7 mM KH2PO4, pH 2.6, 25% ACN (vol/vol); B) 
40 mM KCl, 7 mM KH2PO4, pH 2.6, 25% ACN (vol/vol); C) 100 mM KCl, 7 mM 
KH2PO4, pH 2.6, 25% ACN (vol/vol); D) 600 mM KCl, 7 mM KH2PO4, pH 2.6, 
25% ACN (vol/vol). Prior to the SCX runs, all samples (N = 4) were dissolved in 
900 µL buffer A (1 mL sample loop). A step-gradient was applied that included 60 
min with Buffer A, 60 min with Buffer B, 60 min with Buffer C, and 60 min with 
Buffer D, with 1 min transitions between the different buffer conditions. Fractions 
were collected separately for each of the different buffer conditions (e.g., a buffer 
A fraction, a buffer B fraction, and so on). Fraction C was isolated because 
substance P and all C-terminal peptide products are expected to be +3 charged 
at pH 2.6. This fraction was applied to a C18 Sep Pak cartridge, washed with 
water to desalt the samples, and then eluted with 1 mL of 70:30 H2O/ACN and 
concentrated using a speed vac. It is important to note that the Met on substance 
P becomes nearly 100% oxidized following SCX. The peptide samples were 
dissolved in 0.1% aqueous formic acid (50 mg tissue/20 µL), normalized 
according to the original tissue weight, prior to LC-MS analysis. 
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LC-MS/MS experiments to detect SP c-terminal peptide fragments  
Fractionated spinal cord samples were analyzed using a nano flow LC (Nano LC-
2D, Eksigent Technologies) system coupled to a linear ion trap mass 
spectrometer (LTQ, ThermoFinnigan) following a 10 uL injection. The analytical 
column (Self-pack picofrit column, 75 µm ID, New Objective) was packed 15 cm 
with 3 µm C18 (Magic C18 AQ 200A 3U, Michrom Bioresources Inc). The trap 
column was obtained pre-packed from New Objective Inc. (Integrafrit sample 
trap, C18 5 µm, 100 µm column ID). The samples were trapped at an isocratic 
flow rate of 2 µl/min for 10 minutes and eluted at a flow rate of 300 nl/min via a 
mobile phase gradient of 2 – 50% B in 180 min (Mobile Phase A: 0.1% formic 
acid in water, Mobile Phase B: 0.1% formic acid in acetonitrile). The peptides 
were detected in the positive mode and the mass range for data acquisition was 
set from m/z 400-2000. The data were collected in Top 6 MS2 mode (N = 4) with 
the dynamic exclusion set for 30s, the exclusion size list set to 200, and the 
normalized collision energy for CID set to 35%. The capillary spray voltage was 
set to 2.5 kV. Peptide identification was performed with the SEQUEST algorithm 
with differential modification of methionine to its sulfoxide. The 
uniprotmus_frc.fasta mouse database, concatenated to a reversed decoy 
database, served to estimate a false discovery rate (FDR). Peptides were 
accepted within 1 Da of the expected mass, meeting a series of custom filters on 
ScoreFinal (Sf), -10 Log P, and charge state that attained an average peptide 
FDR of <2% across data sets. Manual inspection of spectra, FDR calculation, 
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and protein inference were performed in Proteomics Browser Suite 2.23 
(ThermoFisher Scientific). We utilized an algorithm written in-house that reveals 
related MSMS spectra (MuQuest; Harvard Proteomics Browser Suite). To 
analyze the spinal cord peptidome to search for SP fragments, we used the 
MSMS data from the in vitro membrane lysate experiments. MuQuest is then 
applied to compare the in vitro MSMS spectra with those of the in vivo data set to 
determine which in vitro MSMS spectra (i.e., which peptides) are present in the in 
vivo samples. The output files are filtered based on charge state, mass to charge 
values, and statistical scores.  
 
Isotope dilution MS (IDMS) to determine endogenous levels of substance P 
and its c-terminal peptide fragments 
The heavy-label versions of SP(1-7), SP(1-9), and substance P were spiked into 
spinal cord samples at the beginning of the peptide isolation process. After fine 
tuning the amount of spiked peptides, it was determined that a final concentration 
of 100 fmol/µL of SP(1-7) and substance P and 25 fmol/µL of SP(1-9) would lead 
to adequate measurements of the peptides using a comparison of the area 
integration for the +2 charge state of the endogenous and heavy labeled 
peptides.. 
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Monitoring C-terminal SP degradation in spinal cord lysates 
Three mouse spinal cords were dounce homogenized in 1.1 mL phosphate 
buffered saline (PBS) on ice and then sonicated for 15 s at 4 ºC. Tissue debris 
was separated by centrifuging the sample at 5,000 x g for 20 min at 4 ºC. The 
soluble fraction was collected after ultracentrifuging the sample at 55,000 x g for 
1 h at 4ºC. The membrane pellet that remained was washed 3x with 600 µL PBS 
by gently covering the pellet. The pellet was then suspended in 400 µL PBS. The 
protein content in the soluble and membrane lysate was quantified by the 
Bradford assay. Substance P (100 µM) was incubated in 1 mg/mL soluble and 
membrane lysates for 1 h at 37ºC. The reactions proceeded at 37ºC for 1 h and 
were quenched with an equal volume of 8 M guanidinium hydrochloride. The 
samples were then desalted via C18 ZipTips (Millipore) and speed vac dried. The 
samples were redissolved in 0.1% formic acid (aq) and analyzed by MALDI-TOF 
MS for substance P-degrading activity (i.e. formation of SP(1-7) and SP(1-9)) 
using the method outlined in “MALDI-TOF MS and LC-MS/MS analysis of in vitro 
peptides” section. 
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Developing a candidate list for the substance P degrading enzymes 
responsible for the formation of SP(1-9) 
The MEROPS database was utilized to devise a candidate list for the enzymes 
that could cleave substance P, forming SP(1-9) in mice (32). The candidate list 
was narrowed based on protein abundance using the following databases: 
www.brain-map.org 
https://www.nextbio.com/b/nextbio.nb 
 
Western blotting to confirm presence of candidate enzymes 
The presence of the candidate enzymes in the mouse spinal cord membrane 
lysate was confirmed by Western blot using the following antibodies: matrix 
metallopreoteinase 8 (MMP8) (Abcam Inc.; rabbit polyclonal), matrix 
metallopreoteinase (MMP9) (Abcam Inc.; rabbit polyclonal), endothelin 
converting enzyme 1 (ECE1) (Abcam Inc.; rabbit polyclonal), endothelin 
converting enzyme 2 (ECE2), (Proteintech Group Inc.; rabbit polyclonal), pitrilysin 
(PITRM1) (Proteintech Group; rabbit polyclonal), neprilysin (CD10) (Abcam Inc.; 
mouse polyclonal). To improve sensitivity/detection, the membrane lysate was 
fractionated using the membrane protein solubilization properties of deoxycholate 
(Alfa Aesar) at different concentrations (1, 4, 12, and 24 mM).  
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Protease inhibitor studies using general enzyme class inhibitors 
The membrane fraction of spinal cord lysates (1 mg/mL) were pre-incubated at 
37 ºC for 30 minutes separately with each the following inhibitors: 10 µM E-64 
(cysteine protease), 1 mM iodoacetamide (cysteine protease), 1 mM o-
phenanthroline (metalloprotease), 10 µM pepstatin A (aspartyl protease), 1 mM 
phenylmethylsulfonyl fluoride (serine protease), 1 mM diisopropylfluorophosphate 
(serine protease), and vehicle (PBS with DMSO for 5% DMSO final concentration 
in reaction). After the pre-incubation with each inhibitor, substance P was added 
to 100 µM final concentration. The reactions proceeded at 37ºC for 1 h and were 
quenched with an equal volume of 8 M guanidinium hydrochloride. The samples 
were then desalted via C18 ZipTips (Millipore, Billerica, MA) and speed vac dried. 
The samples were redissolved in 0.1% formic acid (aq) and analyzed by LC-
MS/MS for subtance P-degrading activity (i.e. formation of SP(1-7) and SP(1-9)) 
using the method outlined in “MALDI-TOF MS and LC-MS/MS analysis of in vitro 
peptides” section. 
 
Protease inhibitor studies using metalloprotease specific enzyme class 
inhibitors 
The membrane fraction of spinal cord lysates (1 mg/mL) were pre-incubated at 
37 ºC for 30 minutes separately with each the following inhibitors at: SM-19712 
(ECE1), phosphoramidon (neprilysin; ECE2), MMP9 inhibitor, TIMP2 (MMP 
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inhibitor), GM6001 (MMP and neprilysin broad inhibitor), chymostatin (pitrilysin), 
captopril (ACE), enalaprilat (ACE), actinonin (Meprin 1A), and vehicle (PBS with 
DMSO for 5% DMSO final concentration in reaction). All inhibitors were present 
at 100 μM except for TIMP2 which was present at 4 μM. After the pre-incubation 
with each inhibitor, either SP(1-11) or SP(1-9) was added to 100 µM final 
concentration. The reactions proceeded at 37ºC for 1 h and were quenched with 
an equal volume of 8 M guanidinium hydrochloride. The samples were then 
desalted via ZipTip C18 (Millipore, ZTC18S096) and speed vac dried. The 
samples were redissolved in 0.1% formic acid (aq) and analyzed by LC-MS/MS 
for SP(1-11) or SP(1-9)-degrading activity. 
 
In vivo and in vitro comparative study of substance P degradation in WT 
and Nep–/– mice spinal cord tissue 
The levels of substance P in WT and Nep–/– mice spinal cord tissue were 
compared by IDMS using Top 6 MS/MS as described previously.  The 
degradation of substance P was compared in WT and Nep–/– mice spinal cord 
membrane lysate using LC-MS/MS analysis.                
 
MALDI-TOF MS and LC-MS/MS analysis of in vitro peptides 
MALDI-TOF MS was performed with α-cyano-4-hydroxycinnamic acid as the 
matrix using 2 µL of a 50 µM reconstituted degradation reaction solution (based 
on initial substance P concentration).  
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 For LC-MS analysis, an Agilent 6220 LC-ESI-TOF instrument was used in 
the positive mode. A Bio-Bond C18 (5 µm, 150 x 2.1 mm) column was used 
together with a precolumn (C18, 3.5 µm, 2 x 20 mm). Following injection of 25 µL 
of 5 µM solutions, the samples were trapped at an isocratic flow rate of 0.1 
ml/min for five minutes and eluted at a flow rate of 0.25 mL/min via a mobile 
phase gradient of 2 – 100% B in 40 min (Mobile Phase A: 0.1% formic acid in 
water, Mobile Phase B: 0.1% formic acid in acetonitrile). MS analysis was 
performed with an electrospray ionization (ESI) source. The capillary voltage was 
set at 4.0 kV and the fragmentor voltage to 100 V. The drying gas temperature 
was 350 °C, the drying gas flow rate was 10 L/min, and the nebulizer pressure 
was 45 psi. Data was collected in the centroid mode using a mass range of 100-
1500 Da. The peptides were analyzed by mass extraction of the +3 charge state. 
 
Using a rhodamine-tagged hydroxamate benzophenone probe (HxBP-Rh) 
to determine GM6001-binding proteins in mice membrane lysates. 
Standard conditions for HxBP-labeling reactions were as follows. Extracted 
membrane lysates (6 mg/mL) were mixed with 100 nM of HxBP-Rh in the 
presence or absence of 100 μM GM6001. The mixtures were preincubated on ice 
for 30 min before irradiation at 365 nm for 1 h (on ice) followed by quenching with 
1/2 vol of standard 3X SDS/PAGE loading buffer (reducing). A control was 
performed in the absence of GM6001 and no irradiation. Labeled proteins were 
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visualized in-gel with fluorescence scanning using a Typhoon flatbed 
fluorescence scanner (GE Healthcare Life Sciences). 
 
GM6001 injection experiments 
 For GM6001 injection experiments, 3-4 month old female WT mice (n=4) were 
fasted overnight. GM6001 was dissolved at a high concentration in DMSO. 
Injections were performed intraperitoneally with a 10 μL/g injection of either 
vehicle (5% DMSO, 95% saline) or 10 mg/mL GM6001 in 5% DMSO, 95% saline 
for a final dose of 100 mg/kg GM6001. Mice were allowed to return to their cages 
for three hours and then spinal cords were isolated as described in the ʻAnimal 
studiesʼ section. 
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